<?xml version="1.0" encoding="UTF-8" ?><!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
	"http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" >
<html><head><title>Side-by-side differences</title><link rel="stylesheet" type="text/css" href="/archive/history.css" /><link rel="stylesheet" type="text/css" href="/archive/sdiff.css" /><script type="text/javascript" src="/archive/common.js"></script><script type="text/javascript" src="/archive/sdiff.js"></script><style>table.sdiff div.sdl0 { margin-left: 0em; }
table.sdiff div.sdl1 { margin-left: 2em; }
table.sdiff div.sdl2 { margin-left: 4em; }
table.sdiff div.sdl3 { margin-left: 6em; }
table.sdiff div.sdl4 { margin-left: 8em; }
table.sdiff div.sdl5 { margin-left: 10em; }
table.sdiff div.sdl6 { margin-left: 12em; }
table.sdiff div.sdl7 { margin-left: 14em; }
table.sdiff div.sdl8 { margin-left: 16em; }
table.sdiff div.sdl9 { margin-left: 18em; }
table.sdiff div.sdl10 { margin-left: 20em; }
table.sdiff div.sdl11 { margin-left: 22em; }
table.sdiff div.sdl12 { margin-left: 24em; }
table.sdiff div.sdl13 { margin-left: 26em; }
table.sdiff div.sdl14 { margin-left: 28em; }
table.sdiff div.sdl15 { margin-left: 30em; }
table.sdiff div.sdl16 { margin-left: 32em; }
table.sdiff div.sdl17 { margin-left: 34em; }
table.sdiff div.sdl18 { margin-left: 36em; }
table.sdiff div.sdl19 { margin-left: 38em; }
</style></head><body class="sdiff">
<div class="navTop"><table class="navTopTriptych"><tr><td class="navTopTriptychL"><img src="/archive/ctgov_logo_ttl.gif" alt="ClinicalTrials.gov" width="360" height="47" /></td><td class="navTopTriptychC" style="background-image: url(/archive/ctgov_logo_ttm.gif)" /><td class="navTopTriptychR"><img src="/archive/ctgov_logo_ttr.gif" alt="Linking patients to medical research" width="314" height="47" /></td></tr></table></div>
<div id="sdiff-links" class="navLinks" /><div id="navLinks" class="navLinks"><a href="/archive/NCT01636609">&#8592; History of this study</a><a href="http://clinicaltrials.gov/show/NCT01636609">&#8593; Current version of this study</a></div><form><div id="sdiff-js-menu" style="display: none"><div><input type="checkbox" id="sdiff-HideUnch-cb" name="sdiff-HideUnch" value="true" onclick="SDiffUpdateHideUnch(&#39;sdiff-HideUnch-cb&#39;)" /><span class="sdiff-label" onclick="SDiffToggleHideUnch(&#39;sdiff-HideUnch-cb&#39;)"> Hide unchanged portions (except top/bottom lines)</span></div><div><input type="checkbox" id="sdiff-HideNonMain-cb" name="sdiff-HideNonMain" value="true" onclick="SDiffUpdateHideNonMain(&#39;sdiff-HideNonMain-cb&#39;)" /><span class="sdiff-label" onclick="SDiffToggleHideNonMain(&#39;sdiff-HideNonMain-cb&#39;)"> Hide non-essential portions (contact info, locations, etc.)</span></div><div style="display:none"><input type="checkbox" id="sdiff-HideKey-cb" name="sdiff-HideKey" value="true" onclick="SDiffUpdateHideKey(&#39;sdiff-HideKey-cb&#39;)" /><span class="sdiff-label" onclick="SDiffToggleHideKey(&#39;sdiff-HideKey-cb&#39;)"> Hide key</span></div></div><h1>Changes to NCT01636609 on 2013_04_24</h1><div id="sdiff-key"><div id="sdiff-key-mb"><img id="sdiff-key-minmax" onclick="SDiffToggleHideKey(&#39;sdiff-HideKey-cb&#39;)" src="/archive/minmax.gif" alt="[+/-]" width="16" height="16" style="display:none" /><h2>Key</h2></div><img id="sdiff-key-img" src="/archive/sdiff-key.gif" alt="Key" /></div><div class="sdiff-changedesc"><em>Type of info changed: </em>Recruitment, Misc.</div><div class="sdiff-view" id="sdiff-full" style="display: none"><table class="sdiff navLinks"><colgroup><col id="h-col" /><col id="a-col" /><col id="b-col" /></colgroup><tr><th class="sdiff-h" /><th class="sdiff-a"><div class="sdiff-prev"><a href="/archive/NCT01636609/2013_03_08/changes" title="Show changes from prior version to this one"><img src="/archive/prev.gif" alt="[Previous]" width="23" height="19" /></a></div><h2>Before</h2><h3><a href="/archive/NCT01636609/2013_03_08">(Updated 2013_03_08)</a></h3></th><th class="sdiff-b"><div class="sdiff-next"><a href="/archive/NCT01636609/2013_05_02/changes" title="Show changes from this version to next one"><img src="/archive/next.gif" alt="[Next]" width="23" height="19" /></a></div><h2>After</h2><h3><a href="/archive/NCT01636609/2013_04_24">(Updated 2013_04_24)</a></h3></th></tr>
<tr class="sdiff-unc" id="sdiff-chunk-f1"><td class="sdiff-h">1</td>
<td class="sdiff-a"><img id="sdiff-collapse-f0A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none" /><img id="sdiff-collapse-f0A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none" /><div class="sdl0 sds">&lt;clinical_study&gt;</div>
<div id="sdiff-collapse-f0A-cdiv" class="sdiff-collapsed" title="The middle 167 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none"></div><div id="sdiff-collapse-f0A-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;study_id&gt;</div>
<div class="sdl2 sds">&lt;org_name&gt;</div>
<div class="sdl3">  MDAnderson</div>
<div class="sdl2 sdz">&lt;/org_name&gt;</div>
<div class="sdl2 sds">&lt;org_full_name&gt;</div>
<div class="sdl3">  M.D. Anderson Cancer Center</div>
<div class="sdl2 sdz">&lt;/org_full_name&gt;</div>
<div class="sdl2 sds">&lt;org_study_id&gt;</div>
<div class="sdl3">  2011-0188</div>
<div class="sdl2 sdz">&lt;/org_study_id&gt;</div>
<div class="sdl2 sds">&lt;nct_id&gt;</div>
<div class="sdl3">  NCT01636609</div>
<div class="sdl2 sdz">&lt;/nct_id&gt;</div>
<div class="sdl1 sdz">&lt;/study_id&gt;</div>
<div class="sdl1 sds">&lt;is_fda_regulated&gt;</div>
<div class="sdl2">  Yes</div>
<div class="sdl1 sdz">&lt;/is_fda_regulated&gt;</div>
<div class="sdl1 sds">&lt;is_section_801&gt;</div>
<div class="sdl2">  Yes</div>
<div class="sdl1 sdz">&lt;/is_section_801&gt;</div>
<div class="sdl1 sds">&lt;delayed_posting&gt;</div>
<div class="sdl2">  No</div>
<div class="sdl1 sdz">&lt;/delayed_posting&gt;</div>
<div class="sdl1 sds">&lt;brief_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Combination Study of Cytarabine and Tosedostat in Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndromes (MDS)</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_title&gt;</div>
<div class="sdl1 sds">&lt;official_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Phase I/II Study of Cytarabine or 5-Azacitidine Combined With Tosedostat to Evaluate the Safety and Tolerability in Older Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndromes (MDS)</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/official_title&gt;</div>
<div class="sdl1 sds">&lt;study_sponsor&gt;</div>
<div class="sdl2 sds">&lt;lead_sponsor&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  M.D. Anderson Cancer Center</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/lead_sponsor&gt;</div>
<div class="sdl2 sds">&lt;sponsor&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  Cell Therapeutics</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/sponsor&gt;</div>
<div class="sdl1 sdz">&lt;/study_sponsor&gt;</div>
<div class="sdl1 sds">&lt;resp_party&gt;</div>
<div class="sdl2 sds">&lt;resp_party_type&gt;</div>
<div class="sdl3">  Sponsor</div>
<div class="sdl2 sdz">&lt;/resp_party_type&gt;</div>
<div class="sdl1 sdz">&lt;/resp_party&gt;</div>
<div class="sdl1 sds">&lt;oversight_info&gt;</div>
<div class="sdl2 sds">&lt;regulatory_authority&gt;</div>
<div class="sdl3">  United States: Food and Drug Administration</div>
<div class="sdl2 sdz">&lt;/regulatory_authority&gt;</div>
<div class="sdl2 sds">&lt;has_dmc&gt;</div>
<div class="sdl3">  Yes</div>
<div class="sdl2 sdz">&lt;/has_dmc&gt;</div>
<div class="sdl1 sdz">&lt;/oversight_info&gt;</div>
<div class="sdl1 sds">&lt;brief_summary&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  The goal of the Phase 1 part of this clinical research study is to learn the highest tolerable dose of cytarabine that can be given with tosedostat and the highest tolerable dose of  5-azacitidine that can be given with tosedostat to patients with AML or MDS.</div>
<div class="sdl3">  </div>
<div class="sdl3">  The goal of the Phase 2 part of the study is to learn if cytarabine with tosedostat and/or 5-azacitidine with tosedostat can help to control the disease.  The safety of these combinations will continue to be studied.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Tosedostat is designed to block the production of proteins that cancer cells need to grow.  Blocking these proteins may cause the cancer cells to die.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Cytarabine is designed to insert itself into DNA (genetic material) of cancer cells and stop the DNA from repairing itself.</div>
<div class="sdl3">  </div>
<div class="sdl3">  5-azacitidine is designed to block certain proteins in cancer cells whose job is to stop the function of the tumor-fighting proteins.  By blocking these proteins, the tumor-fighting genes may be able to work better.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_summary&gt;</div>
<div class="sdl1 sds">&lt;detailed_descr&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Study Groups:</div>
<div class="sdl3">  If you are found to be eligible to take part in this study, you will be assigned to receive cytarabine with tosedostat (Group 1) or 5-azacitidine (Group 2). Your doctor will decide which drugs you will receive.</div>
<div class="sdl3">  </div>
<div class="sdl3">  You will be assigned to a study phase based on when you join this study.  Up to 2 groups of about 18 participants will be enrolled in the Phase I portion of the study, and up to 60 participants will be enrolled in Phase II.</div>
<div class="sdl3">  </div>
<div class="sdl3">  If you are enrolled in the Phase I portion, the dose of cytarabine or 5-azacitidine you receive will depend on when you joined this study.  The first group of participants will receive the lowest dose level of cytarabine or 5-azacitidine.  The second group will receive a higher dose of cytarabine or 5-azacitidine than the group before it, if no intolerable side effects were seen.  </div>
<div class="sdl3">  </div>
<div class="sdl3">  If you are enrolled in the Phase II portion, you will receive cytarabine or 5-azacitidine at the highest dose that was tolerated in the Phase I portion.</div>
<div class="sdl3">  </div>
<div class="sdl3">  All participants will receive the same dose level of tosedostat.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Study Drug Administration:</div>
<div class="sdl3">  In this study you receive induction therapy to try to control the disease and cause remission (the point when tests and/or your doctor cannot find signs of the disease).  If the disease is in remission, you may receive more cycles (called Consolidation Cycles) to help keep the disease under control.  </div>
<div class="sdl3">  </div>
<div class="sdl3">  Each study cycle is about 4 weeks long, but may be longer depending on your response to the study drug(s). </div>
<div class="sdl3">  </div>
<div class="sdl3">  Participants in both groups will take tosedostat by mouth 1 time every day.   You should take the pills at about the same time every day (about 24 hours between doses) during a meal or just after a meal.  You may take the drug with water.  </div>
<div class="sdl3">  </div>
<div class="sdl3">  You will be given a study drug diary, so you can record when you take each dose. You should complete this diary every day and bring it with you to all study visits. You should also bring any unused tosedostat to each study visit including all empty pots.</div>
<div class="sdl3">  </div>
<div class="sdl3">  You should not take more than your assigned number of capsules within a 24-hour period.  If you accidentally take more on 1 day, you should tell your study doctor right away. If you miss a dose in the morning then you can take the dose up until late afternoon (5pm). After that time the dose should be omitted and you should continue your drug schedule as usual the following day.  Do not try to &amp;quot;make up&amp;quot; the missed dose after 5pm.</div>
<div class="sdl3">  </div>
<div class="sdl3">  If you are in Group 1, you will also receive cytarabine by a needle under the skin 2 times each day on Days 1-10.  </div>
<div class="sdl3">  </div>
<div class="sdl3">  If you are in Group 2, you will also receive 5-azacitidine by vein over 10-40 minutes or by a needle under the skin each day on Days 1-7.  </div>
<div class="sdl3">  </div>
<div class="sdl3">  After induction, the amount of tosedostat you receive may be increased. Your doctor may decide to stop the cytarabine or 5-azacitidine and continue with tosedostat alone.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Study Visits:</div>
<div class="sdl3">  On Day 1 of Cycle 1:</div>
<div class="sdl3">  -You will have a physical exam, including measurement of your vital signs.</div>
<div class="sdl3">  -Blood (about 1 teaspoon) will be drawn for routine tests.</div>
<div class="sdl3">  -Blood (about 1 teaspoon) will be drawn for pharmacokinetic (PK) testing.  PK testing measures the amount of study drug in your body at different time points.</div>
<div class="sdl3">  -Your performance status will be recorded.</div>
<div class="sdl3">  -Your medical history will be recorded.</div>
<div class="sdl3">  -You will be asked about any drugs you may be taking.</div>
<div class="sdl3">  </div>
<div class="sdl3">  On Days 8, 15, and 22 of Cycle 1 (+/- 2 days):</div>
<div class="sdl3">  -Your vital signs will be measured.</div>
<div class="sdl3">  -Blood (about 1 teaspoon) will be drawn for routine tests.</div>
<div class="sdl3">  -You will have an ECG.</div>
<div class="sdl3">  -You will be asked about any drugs you may be taking and side effects you may be having.</div>
<div class="sdl3">  -On Day 8 only, you will have a physical exam.</div>
<div class="sdl3">  -On Day 15 only, blood (about 1 teaspoon) will be drawn for PK testing.</div>
<div class="sdl3">  </div>
<div class="sdl3">  On Day 28 of Cycle 1 (+/- 5 days) (this visit may be combined with the Day 1 of Cycle 2 visit):</div>
<div class="sdl3">  -You will have a physical exam, including measurement of your vital signs.</div>
<div class="sdl3">  -Blood (about 1 teaspoon) will be drawn for routine tests.</div>
<div class="sdl3">  -Blood (about 1 teaspoon) will be drawn for PK testing.</div>
<div class="sdl3">  -Your performance status will be recorded.</div>
<div class="sdl3">  -You will be asked about any drugs you may be taking and side effects you may be having.</div>
<div class="sdl3">  -You will have an ECG.</div>
<div class="sdl3">  -You will have a bone marrow biopsy/aspiration to check the status of the disease.</div>
<div class="sdl3">  </div>
<div class="sdl3">  On Day 1 of Cycles 2 and beyond (+/- 5 days):</div>
<div class="sdl3">  -You will have a physical exam, including measurement of your vital signs.</div>
<div class="sdl3">  -Blood (about 1 teaspoon) will be drawn for routine tests.</div>
<div class="sdl3">  -Your performance status will be recorded.</div>
<div class="sdl3">  -You will be asked about any drugs you may be taking and side effects you may be having.</div>
<div class="sdl3">  -You will have an ECG.</div>
<div class="sdl3">  -During Cycles 2 and 3 only, blood (about 1 teaspoon) will be drawn for PK testing.</div>
<div class="sdl3">  -During odd-numbered cycles (3, 5, 7 and so on), you will have a bone marrow biopsy/aspiration to check the status of the disease.</div>
<div class="sdl3">  </div>
<div class="sdl3">  If your study doctor feels it is needed, you may have extra clinic visits, tests, or procedures. </div>
<div class="sdl3">  </div>
<div class="sdl3">  Participants Receiving Home Care:</div>
<div class="sdl3">  If you will receive the first cycle at home, you will be called on Day 14 (+/- 5 days) of Cycle 1 and asked about any side effects you may be having. This call will take about 15 minutes.</div>
<div class="sdl3">  </div>
<div class="sdl3">  If you are receiving home care, you will return to MD Anderson before the start of each cycle During Cycles 1-3, then every 3 cycles (+/- 1 cycle) until 1 year after the start of therapy, and then every 6 months (+/- 1 month) after that.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Length of Study:</div>
<div class="sdl3">  You may take the study drug for up to 1 year. You will be taken off study early if the disease gets worse, if you have intolerable side effects, if you are not able to follow the study directions, or if the study doctor thinks it is in your best interest.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Your participation on the study will be over once you have completed the follow-up.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Follow-Up:</div>
<div class="sdl3">  About 28 days after your last dose of tosedostat:</div>
<div class="sdl3">  -You will have a physical exam, including measurement of your vital signs.</div>
<div class="sdl3">  -Your performance status will be recorded.</div>
<div class="sdl3">  -Blood (about 1 teaspoon) will be drawn for routine tests.</div>
<div class="sdl3">  -You will have an ECG. </div>
<div class="sdl3">  -You will be asked about any side effect that you may have had and any drugs you may be taking. </div>
<div class="sdl3">  </div>
<div class="sdl3">  Once you have completed the follow-up visit, the study staff may contact you by telephone every 3-6 months to check the status of your health.  Keeping in touch with you and checking on your condition will help researchers look at the long-term effects of the study drug.</div>
<div class="sdl3">  </div>
<div class="sdl3">  This is an investigational study.  Tosedostat is not FDA approved or commercially available.  At this time, tosedostat is only being used in research. Cytarabine is FDA approved and commercially available for certain types of MDS and AML. 5-azacitidine is FDA approved and commercially available for certain types of MDS and AML. </div>
<div class="sdl3">  </div>
<div class="sdl3">  Up to 96 patients will take part in this study. All patients will be enrolled at MD Anderson.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/detailed_descr&gt;</div>
<div class="sdl1 sds">&lt;status_block&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  Recruiting</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
</div><div class="sdl2 sds">&lt;date&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-f0B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none" /><img id="sdiff-collapse-f0B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none" /><div class="sdl0 sds">&lt;clinical_study&gt;</div>
<div id="sdiff-collapse-f0B-cdiv" class="sdiff-collapsed" title="The middle 167 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none"></div><div id="sdiff-collapse-f0B-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;study_id&gt;</div>
<div class="sdl2 sds">&lt;org_name&gt;</div>
<div class="sdl3">  MDAnderson</div>
<div class="sdl2 sdz">&lt;/org_name&gt;</div>
<div class="sdl2 sds">&lt;org_full_name&gt;</div>
<div class="sdl3">  M.D. Anderson Cancer Center</div>
<div class="sdl2 sdz">&lt;/org_full_name&gt;</div>
<div class="sdl2 sds">&lt;org_study_id&gt;</div>
<div class="sdl3">  2011-0188</div>
<div class="sdl2 sdz">&lt;/org_study_id&gt;</div>
<div class="sdl2 sds">&lt;nct_id&gt;</div>
<div class="sdl3">  NCT01636609</div>
<div class="sdl2 sdz">&lt;/nct_id&gt;</div>
<div class="sdl1 sdz">&lt;/study_id&gt;</div>
<div class="sdl1 sds">&lt;is_fda_regulated&gt;</div>
<div class="sdl2">  Yes</div>
<div class="sdl1 sdz">&lt;/is_fda_regulated&gt;</div>
<div class="sdl1 sds">&lt;is_section_801&gt;</div>
<div class="sdl2">  Yes</div>
<div class="sdl1 sdz">&lt;/is_section_801&gt;</div>
<div class="sdl1 sds">&lt;delayed_posting&gt;</div>
<div class="sdl2">  No</div>
<div class="sdl1 sdz">&lt;/delayed_posting&gt;</div>
<div class="sdl1 sds">&lt;brief_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Combination Study of Cytarabine and Tosedostat in Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndromes (MDS)</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_title&gt;</div>
<div class="sdl1 sds">&lt;official_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Phase I/II Study of Cytarabine or 5-Azacitidine Combined With Tosedostat to Evaluate the Safety and Tolerability in Older Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndromes (MDS)</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/official_title&gt;</div>
<div class="sdl1 sds">&lt;study_sponsor&gt;</div>
<div class="sdl2 sds">&lt;lead_sponsor&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  M.D. Anderson Cancer Center</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/lead_sponsor&gt;</div>
<div class="sdl2 sds">&lt;sponsor&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  Cell Therapeutics</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/sponsor&gt;</div>
<div class="sdl1 sdz">&lt;/study_sponsor&gt;</div>
<div class="sdl1 sds">&lt;resp_party&gt;</div>
<div class="sdl2 sds">&lt;resp_party_type&gt;</div>
<div class="sdl3">  Sponsor</div>
<div class="sdl2 sdz">&lt;/resp_party_type&gt;</div>
<div class="sdl1 sdz">&lt;/resp_party&gt;</div>
<div class="sdl1 sds">&lt;oversight_info&gt;</div>
<div class="sdl2 sds">&lt;regulatory_authority&gt;</div>
<div class="sdl3">  United States: Food and Drug Administration</div>
<div class="sdl2 sdz">&lt;/regulatory_authority&gt;</div>
<div class="sdl2 sds">&lt;has_dmc&gt;</div>
<div class="sdl3">  Yes</div>
<div class="sdl2 sdz">&lt;/has_dmc&gt;</div>
<div class="sdl1 sdz">&lt;/oversight_info&gt;</div>
<div class="sdl1 sds">&lt;brief_summary&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  The goal of the Phase 1 part of this clinical research study is to learn the highest tolerable dose of cytarabine that can be given with tosedostat and the highest tolerable dose of  5-azacitidine that can be given with tosedostat to patients with AML or MDS.</div>
<div class="sdl3">  </div>
<div class="sdl3">  The goal of the Phase 2 part of the study is to learn if cytarabine with tosedostat and/or 5-azacitidine with tosedostat can help to control the disease.  The safety of these combinations will continue to be studied.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Tosedostat is designed to block the production of proteins that cancer cells need to grow.  Blocking these proteins may cause the cancer cells to die.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Cytarabine is designed to insert itself into DNA (genetic material) of cancer cells and stop the DNA from repairing itself.</div>
<div class="sdl3">  </div>
<div class="sdl3">  5-azacitidine is designed to block certain proteins in cancer cells whose job is to stop the function of the tumor-fighting proteins.  By blocking these proteins, the tumor-fighting genes may be able to work better.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_summary&gt;</div>
<div class="sdl1 sds">&lt;detailed_descr&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Study Groups:</div>
<div class="sdl3">  If you are found to be eligible to take part in this study, you will be assigned to receive cytarabine with tosedostat (Group 1) or 5-azacitidine (Group 2). Your doctor will decide which drugs you will receive.</div>
<div class="sdl3">  </div>
<div class="sdl3">  You will be assigned to a study phase based on when you join this study.  Up to 2 groups of about 18 participants will be enrolled in the Phase I portion of the study, and up to 60 participants will be enrolled in Phase II.</div>
<div class="sdl3">  </div>
<div class="sdl3">  If you are enrolled in the Phase I portion, the dose of cytarabine or 5-azacitidine you receive will depend on when you joined this study.  The first group of participants will receive the lowest dose level of cytarabine or 5-azacitidine.  The second group will receive a higher dose of cytarabine or 5-azacitidine than the group before it, if no intolerable side effects were seen.  </div>
<div class="sdl3">  </div>
<div class="sdl3">  If you are enrolled in the Phase II portion, you will receive cytarabine or 5-azacitidine at the highest dose that was tolerated in the Phase I portion.</div>
<div class="sdl3">  </div>
<div class="sdl3">  All participants will receive the same dose level of tosedostat.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Study Drug Administration:</div>
<div class="sdl3">  In this study you receive induction therapy to try to control the disease and cause remission (the point when tests and/or your doctor cannot find signs of the disease).  If the disease is in remission, you may receive more cycles (called Consolidation Cycles) to help keep the disease under control.  </div>
<div class="sdl3">  </div>
<div class="sdl3">  Each study cycle is about 4 weeks long, but may be longer depending on your response to the study drug(s). </div>
<div class="sdl3">  </div>
<div class="sdl3">  Participants in both groups will take tosedostat by mouth 1 time every day.   You should take the pills at about the same time every day (about 24 hours between doses) during a meal or just after a meal.  You may take the drug with water.  </div>
<div class="sdl3">  </div>
<div class="sdl3">  You will be given a study drug diary, so you can record when you take each dose. You should complete this diary every day and bring it with you to all study visits. You should also bring any unused tosedostat to each study visit including all empty pots.</div>
<div class="sdl3">  </div>
<div class="sdl3">  You should not take more than your assigned number of capsules within a 24-hour period.  If you accidentally take more on 1 day, you should tell your study doctor right away. If you miss a dose in the morning then you can take the dose up until late afternoon (5pm). After that time the dose should be omitted and you should continue your drug schedule as usual the following day.  Do not try to &amp;quot;make up&amp;quot; the missed dose after 5pm.</div>
<div class="sdl3">  </div>
<div class="sdl3">  If you are in Group 1, you will also receive cytarabine by a needle under the skin 2 times each day on Days 1-10.  </div>
<div class="sdl3">  </div>
<div class="sdl3">  If you are in Group 2, you will also receive 5-azacitidine by vein over 10-40 minutes or by a needle under the skin each day on Days 1-7.  </div>
<div class="sdl3">  </div>
<div class="sdl3">  After induction, the amount of tosedostat you receive may be increased. Your doctor may decide to stop the cytarabine or 5-azacitidine and continue with tosedostat alone.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Study Visits:</div>
<div class="sdl3">  On Day 1 of Cycle 1:</div>
<div class="sdl3">  -You will have a physical exam, including measurement of your vital signs.</div>
<div class="sdl3">  -Blood (about 1 teaspoon) will be drawn for routine tests.</div>
<div class="sdl3">  -Blood (about 1 teaspoon) will be drawn for pharmacokinetic (PK) testing.  PK testing measures the amount of study drug in your body at different time points.</div>
<div class="sdl3">  -Your performance status will be recorded.</div>
<div class="sdl3">  -Your medical history will be recorded.</div>
<div class="sdl3">  -You will be asked about any drugs you may be taking.</div>
<div class="sdl3">  </div>
<div class="sdl3">  On Days 8, 15, and 22 of Cycle 1 (+/- 2 days):</div>
<div class="sdl3">  -Your vital signs will be measured.</div>
<div class="sdl3">  -Blood (about 1 teaspoon) will be drawn for routine tests.</div>
<div class="sdl3">  -You will have an ECG.</div>
<div class="sdl3">  -You will be asked about any drugs you may be taking and side effects you may be having.</div>
<div class="sdl3">  -On Day 8 only, you will have a physical exam.</div>
<div class="sdl3">  -On Day 15 only, blood (about 1 teaspoon) will be drawn for PK testing.</div>
<div class="sdl3">  </div>
<div class="sdl3">  On Day 28 of Cycle 1 (+/- 5 days) (this visit may be combined with the Day 1 of Cycle 2 visit):</div>
<div class="sdl3">  -You will have a physical exam, including measurement of your vital signs.</div>
<div class="sdl3">  -Blood (about 1 teaspoon) will be drawn for routine tests.</div>
<div class="sdl3">  -Blood (about 1 teaspoon) will be drawn for PK testing.</div>
<div class="sdl3">  -Your performance status will be recorded.</div>
<div class="sdl3">  -You will be asked about any drugs you may be taking and side effects you may be having.</div>
<div class="sdl3">  -You will have an ECG.</div>
<div class="sdl3">  -You will have a bone marrow biopsy/aspiration to check the status of the disease.</div>
<div class="sdl3">  </div>
<div class="sdl3">  On Day 1 of Cycles 2 and beyond (+/- 5 days):</div>
<div class="sdl3">  -You will have a physical exam, including measurement of your vital signs.</div>
<div class="sdl3">  -Blood (about 1 teaspoon) will be drawn for routine tests.</div>
<div class="sdl3">  -Your performance status will be recorded.</div>
<div class="sdl3">  -You will be asked about any drugs you may be taking and side effects you may be having.</div>
<div class="sdl3">  -You will have an ECG.</div>
<div class="sdl3">  -During Cycles 2 and 3 only, blood (about 1 teaspoon) will be drawn for PK testing.</div>
<div class="sdl3">  -During odd-numbered cycles (3, 5, 7 and so on), you will have a bone marrow biopsy/aspiration to check the status of the disease.</div>
<div class="sdl3">  </div>
<div class="sdl3">  If your study doctor feels it is needed, you may have extra clinic visits, tests, or procedures. </div>
<div class="sdl3">  </div>
<div class="sdl3">  Participants Receiving Home Care:</div>
<div class="sdl3">  If you will receive the first cycle at home, you will be called on Day 14 (+/- 5 days) of Cycle 1 and asked about any side effects you may be having. This call will take about 15 minutes.</div>
<div class="sdl3">  </div>
<div class="sdl3">  If you are receiving home care, you will return to MD Anderson before the start of each cycle During Cycles 1-3, then every 3 cycles (+/- 1 cycle) until 1 year after the start of therapy, and then every 6 months (+/- 1 month) after that.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Length of Study:</div>
<div class="sdl3">  You may take the study drug for up to 1 year. You will be taken off study early if the disease gets worse, if you have intolerable side effects, if you are not able to follow the study directions, or if the study doctor thinks it is in your best interest.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Your participation on the study will be over once you have completed the follow-up.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Follow-Up:</div>
<div class="sdl3">  About 28 days after your last dose of tosedostat:</div>
<div class="sdl3">  -You will have a physical exam, including measurement of your vital signs.</div>
<div class="sdl3">  -Your performance status will be recorded.</div>
<div class="sdl3">  -Blood (about 1 teaspoon) will be drawn for routine tests.</div>
<div class="sdl3">  -You will have an ECG. </div>
<div class="sdl3">  -You will be asked about any side effect that you may have had and any drugs you may be taking. </div>
<div class="sdl3">  </div>
<div class="sdl3">  Once you have completed the follow-up visit, the study staff may contact you by telephone every 3-6 months to check the status of your health.  Keeping in touch with you and checking on your condition will help researchers look at the long-term effects of the study drug.</div>
<div class="sdl3">  </div>
<div class="sdl3">  This is an investigational study.  Tosedostat is not FDA approved or commercially available.  At this time, tosedostat is only being used in research. Cytarabine is FDA approved and commercially available for certain types of MDS and AML. 5-azacitidine is FDA approved and commercially available for certain types of MDS and AML. </div>
<div class="sdl3">  </div>
<div class="sdl3">  Up to 96 patients will take part in this study. All patients will be enrolled at MD Anderson.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/detailed_descr&gt;</div>
<div class="sdl1 sds">&lt;status_block&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  Recruiting</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
</div><div class="sdl2 sds">&lt;date&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-f2"><td class="sdiff-h">2</td>
<td class="sdiff-a"><div class="sdl3"><span class="sdwc">2013-03</span> </div>
</td>
<td class="sdiff-b"><div class="sdl3"><span class="sdwc">2013-04</span> </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-f3"><td class="sdiff-h">3</td>
<td class="sdiff-a"><img id="sdiff-collapse-f170A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f170&#39;)" style="display:none" /><img id="sdiff-collapse-f170A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f170&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/date&gt;</div>
<div id="sdiff-collapse-f170A-cdiv" class="sdiff-collapsed" title="The middle 383 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f170&#39;)" style="display:none"></div><div id="sdiff-collapse-f170A-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/status_block&gt;</div>
<div class="sdl1 sds">&lt;start_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2012-11</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/start_date&gt;</div>
<div class="sdl1 sda">&lt;primary_compl_date</div>
<div class="sdl1"> type=&quot;Anticipated&quot;</div>
<div class="sdl1">&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2018-11</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/primary_compl_date&gt;</div>
<div class="sdl1 sds">&lt;phase_block&gt;</div>
<div class="sdl2 sds">&lt;phase&gt;</div>
<div class="sdl3">  Phase 1</div>
<div class="sdl2 sdz">&lt;/phase&gt;</div>
<div class="sdl2 sds">&lt;phase&gt;</div>
<div class="sdl3">  Phase 2</div>
<div class="sdl2 sdz">&lt;/phase&gt;</div>
<div class="sdl1 sdz">&lt;/phase_block&gt;</div>
<div class="sdl1 sds">&lt;study_type&gt;</div>
<div class="sdl2">  Interventional</div>
<div class="sdl1 sdz">&lt;/study_type&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Treatment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Randomized</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Open Label</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Single Group Assignment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Safety/Efficacy Study</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;number_of_arms&gt;</div>
<div class="sdl2">  2</div>
<div class="sdl1 sdz">&lt;/number_of_arms&gt;</div>
<div class="sdl1 sds">&lt;primary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Maximum Tolerated Dose (MTD)</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  28 days</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Maximum tolerated daily oral dose defined as &amp;lt;33% of patients experiencing a dose limiting toxicity (DLT) during Cycle 1.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  Yes</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/primary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Anti-Tumor Effects</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  28 days</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Response rate estimated by Bayesian posterior estimates, along with the 95% credible intervals for the two treatment arms. Survival or times to failure and time to progression functions estimated using the Kaplan-Meier method. Toxicity reported by type, frequency and severity. Highest toxicity grades per patient per course tabulated for selected adverse events and laboratory measurements.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  Yes</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sda">&lt;enrollment</div>
<div class="sdl1"> type=&quot;Anticipated&quot;</div>
<div class="sdl1">&gt;</div>
<div class="sdl2">  96</div>
<div class="sdl1 sdz">&lt;/enrollment&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Leukemia</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;arm_group&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Cytarabine + Tosedostat</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_type&gt;</div>
<div class="sdl3">  Experimental</div>
<div class="sdl2 sdz">&lt;/arm_type&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Phase I Arm A: Starting dose of Cytarabine 7.5 mg subcutaneous (SQ) twice daily (BID) for 10 days every 28 days. Dose escalation will proceed up to the Target dose level (dose level 0) 10 mg SQ BID for 10 days.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Phase II (Randomized) Starting dose of Cytarabine: Maximum tolerated dose from Phase I.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Phase I and II Tosedostat: 120 mg by mouth daily. After the first 4 weeks of therapy, a dose escalation to 180 mg daily may be considered for patients not achieving a CR provided the patient has not experienced any grade &amp;gt;/= 3 toxicity. Such instances should be discussed with the principal investigator and the sponsor and assessed on a case-by-case basis.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl1 sdz">&lt;/arm_group&gt;</div>
<div class="sdl1 sds">&lt;arm_group&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  5-Azacytidine + Tosedostat</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_type&gt;</div>
<div class="sdl3">  Experimental</div>
<div class="sdl2 sdz">&lt;/arm_type&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Phase I Arm B: Starting dose of 5-azacytidine 50 mg/m2 by vein (IV) or subcutaneously (SQ) daily for 7 days, on days 1-7 every 28 days. Dose escalation will proceed up to the Target dose level (dose level 0) 75 mg/m2 IV (or SQ) daily for 7 days, on days 1-7.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Phase II (Randomized) Starting dose of 5-azacytidine:  Maximum tolerated dose from Phase I.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Phase I and II Tosedostat: 120 mg by mouth daily. After the first 4 weeks of therapy, a dose escalation to 180 mg daily may be considered for patients not achieving a CR provided the patient has not experienced any grade &amp;gt;/= 3 toxicity. Such instances should be discussed with the principal investigator and the sponsor and assessed on a case-by-case basis.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl1 sdz">&lt;/arm_group&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  Cytarabine</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Phase I Arm A: Starting dose of Cytarabine 7.5 mg subcutaneous (SQ) twice daily (BID) for 10 days every 28 days. Dose escalation will proceed up to the Target dose level (dose level 0) 10 mg SQ BID for 10 days.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Phase II (Randomized) Starting dose of Cytarabine: Maximum tolerated dose from Phase I.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Cytarabine + Tosedostat</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  Ara-C</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  Cytosar</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  DepoCyt</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  Cytosine Arabinosine Hydrochloride</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  5-Azacytidine</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Phase I Arm B: Starting dose of 5-azacytidine 50 mg/m2 by vein (IV) or subcutaneously (SQ) daily for 7 days, on days 1-7 every 28 days. Dose escalation will proceed up to the Target dose level (dose level 0) 75 mg/m2 IV (or SQ) daily for 7 days, on days 1-7.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Phase II (Randomized) Starting dose of 5-azacytidine: Maximum tolerated dose from Phase I.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  5-Azacytidine + Tosedostat</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  Azacitidine</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  5-aza</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  Vidaza</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  5-AZC</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  AZA-CR</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  Ladakamycin</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  NSC-102816</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  Tosedostat</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Phase I: 120 mg by mouth daily.  After the first 4 weeks of therapy, a dose escalation to 180 mg daily may be considered for patients not achieving a CR provided the patient has not experienced any grade &amp;gt;/= 3 toxicity.  Such instances should be discussed with the principal investigator and the sponsor and assessed on a case-by-case basis.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Phase II: 120 mg by mouth daily. 120 mg by mouth daily during induction (i.e., first 28 days of therapy).  After the first 4 weeks of therapy, a dose escalation to 180 mg daily may be considered for patients not achieving a CR provided the patient has not experienced any grade &amp;gt;/= 3 toxicity.  Such instances should be discussed with the principal investigator and the sponsor and assessed on a case-by-case basis.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Cytarabine + Tosedostat</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  5-Azacytidine + Tosedostat</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;eligibility&gt;</div>
<div class="sdl2 sds">&lt;criteria&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Inclusion Criteria:</div>
<div class="sdl4">  </div>
<div class="sdl4">  1)	Signed, informed consent must be obtained prior to any study specific procedures.</div>
<div class="sdl4">  </div>
<div class="sdl4">  2)	For the phase I portion of the study patients should have failed any number of prior therapies, which should include at least the following: 1. Patients with MDS should have failed prior therapy with a hypomethylating agent and/or with lenalidomide. 2. Patients with AML should have failed any prior induction therapy or have relapsed after prior therapy. 3. Patients with MDS who received therapy with a hypomethylating agent and progress to AML are eligible at the time of diagnosis of AML regardless of any prior therapy for AML. 4. Patients with any of the eligible diagnoses who have received no prior therapy are eligible if not candidates to receive standard therapy or if they refuse standard chemotherapy.</div>
<div class="sdl4">  </div>
<div class="sdl4">  3)	For the phase II Portion of the study, only patients who are previously untreated for AML. 1. Patients with history of MDS who received therapy for MDS and progressed to AML are eligible at the time of diagnosis of AML. Only induction chemotherapy administered for AML will be considered for considerations of eligibility regarding prior therapy. Patients who received therapy for MDS before transforming to AML (e.g., with hypomethylating agents or lenalidomide) are eligible.</div>
<div class="sdl4">  </div>
<div class="sdl4">  4)	ECOG performance status of 0-2.</div>
<div class="sdl4">  </div>
<div class="sdl4">  5)	Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must use acceptable contraceptive methods (abstinence, intrauterine device [IUD], oral contraceptive or double barrier device) while on study and must continue to do so for 3 months after stopping study drug, and must have a negative urine or serum pregnancy test within 2 weeks prior to beginning treatment on this trial. Sexually active men must also use acceptable contraceptive methods for the duration of time on study. Pregnant and nursing patients are excluded because the effects of tosedostat on a fetus or nursing child are unknown.</div>
<div class="sdl4">  </div>
<div class="sdl4">  6)	Patients must have been off chemotherapy for 2 weeks prior to entering this study, unless there is evidence of rapidly progressive disease, and must have recovered from the toxic effects of that therapy to at least grade 1. Use of hydroxyurea for patients with rapidly proliferative disease is allowed before the start of study therapy and for the first four weeks on therapy.</div>
<div class="sdl4">  </div>
<div class="sdl4">  7)	Patients must have the following clinical laboratory values unless considered due to leukemic organ involvement: 1. Serum creatinine &amp;lt;/= 2.0 mg/dl. 2. Total bilirubin &amp;lt;/= 1.5x the upper limit of normal unless considered due to Gilbert&amp;apos;s syndrome. 3. Alanine aminotransferase (ALT), or aspartate aminotransferase (AST) &amp;lt;/= 3x the upper limit of normal.</div>
<div class="sdl4">  </div>
<div class="sdl4">  8)	Age &amp;gt;/= 60 years</div>
<div class="sdl4">  </div>
<div class="sdl4">  9)	Left ventricular ejection fraction (LVEF) &amp;gt;/= 50% within 28 days prior to first dose of study drug administration</div>
<div class="sdl4">  </div>
<div class="sdl4">  10)	Patient is able to comply with all study procedures including study drug administration, visits and tests</div>
<div class="sdl4">  </div>
<div class="sdl4">  Exclusion Criteria:</div>
<div class="sdl4">  </div>
<div class="sdl4">  1)	Uncontrolled intercurrent illness including, but not limited to uncontrolled infection, symptomatic congestive heart failure (New York Heart Association Class III or IV), or psychiatric illness/social situations that would limit compliance with study requirements.</div>
<div class="sdl4">  </div>
<div class="sdl4">  2)	Active heart disease including myocardial infarction within previous 3 months, symptomatic coronary artery disease, clinically significant arrhythmias not controlled by medication, or uncontrolled congestive heart failure (New York Heart Association Class III or IV).</div>
<div class="sdl4">  </div>
<div class="sdl4">  3)	Patients with APL (FAB type M3) or CML in blast crisis.</div>
<div class="sdl4">  </div>
<div class="sdl4">  4)	Significant gastrointestinal disorders that may interfere with absorption of tosedostat.</div>
<div class="sdl4">  </div>
<div class="sdl4">  5)	Patients who can receive an allogeneic stem cell transplant within 4 weeks.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/criteria&gt;</div>
<div class="sdl2 sds">&lt;healthy_volunteers&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/healthy_volunteers&gt;</div>
<div class="sdl2 sds">&lt;gender&gt;</div>
<div class="sdl3">  Both</div>
<div class="sdl2 sdz">&lt;/gender&gt;</div>
<div class="sdl2 sds">&lt;minimum_age&gt;</div>
<div class="sdl3">  60 Years</div>
<div class="sdl2 sdz">&lt;/minimum_age&gt;</div>
<div class="sdl2 sds">&lt;maximum_age&gt;</div>
<div class="sdl2 sdz">&lt;/maximum_age&gt;</div>
<div class="sdl1 sdz">&lt;/eligibility&gt;</div>
<div class="sdl1 sds">&lt;investigator&gt;</div>
<div class="sdl2 sds">&lt;role&gt;</div>
<div class="sdl3">  Principal Investigator</div>
<div class="sdl2 sdz">&lt;/role&gt;</div>
<div class="sdl2 sds">&lt;name&gt;</div>
<div class="sdl3">  Jorge Cortes, MD</div>
<div class="sdl2 sdz">&lt;/name&gt;</div>
<div class="sdl2 sds">&lt;affiliation&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  UT MD Anderson Cancer Center</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/affiliation&gt;</div>
<div class="sdl1 sdz">&lt;/investigator&gt;</div>
<div class="sdl1 sds">&lt;contact&gt;</div>
<div class="sdl2 sds">&lt;name&gt;</div>
<div class="sdl3">  Jorge Cortes, MD</div>
<div class="sdl2 sdz">&lt;/name&gt;</div>
<div class="sdl2 sds">&lt;phone&gt;</div>
<div class="sdl3">  713-794-5783</div>
<div class="sdl2 sdz">&lt;/phone&gt;</div>
<div class="sdl2 sds">&lt;phone_ext&gt;</div>
<div class="sdl2 sdz">&lt;/phone_ext&gt;</div>
<div class="sdl2 sds">&lt;email&gt;</div>
<div class="sdl2 sdz">&lt;/email&gt;</div>
<div class="sdl1 sdz">&lt;/contact&gt;</div>
<div class="sdl1 sds">&lt;location&gt;</div>
<div class="sdl2 sds">&lt;facility&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  UT MD Anderson Cancer Center</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl3 sds">&lt;address&gt;</div>
<div class="sdl4 sds">&lt;city&gt;</div>
<div class="sdl5">  Houston</div>
<div class="sdl4 sdz">&lt;/city&gt;</div>
<div class="sdl4 sds">&lt;state&gt;</div>
<div class="sdl5">  Texas</div>
<div class="sdl4 sdz">&lt;/state&gt;</div>
<div class="sdl4 sds">&lt;zip&gt;</div>
<div class="sdl5">  77030</div>
<div class="sdl4 sdz">&lt;/zip&gt;</div>
<div class="sdl4 sds">&lt;country&gt;</div>
<div class="sdl5">  United States</div>
<div class="sdl4 sdz">&lt;/country&gt;</div>
<div class="sdl3 sdz">&lt;/address&gt;</div>
<div class="sdl2 sdz">&lt;/facility&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  Recruiting</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
<div class="sdl1 sdz">&lt;/location&gt;</div>
<div class="sdl1 sds">&lt;see_also&gt;</div>
<div class="sdl2 sds">&lt;annotation&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  UT MD Anderson Cancer Center Website</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/annotation&gt;</div>
<div class="sdl2 sds">&lt;url&gt;</div>
<div class="sdl3">  http://www.mdanderson.org</div>
<div class="sdl2 sdz">&lt;/url&gt;</div>
<div class="sdl1 sdz">&lt;/see_also&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Leukemia</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Acute Myeloid Leukemia</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  AML</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Myelodysplastic Syndromes</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  MDS</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Relapsed</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Refractory</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Cytarabine</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  ARA-C</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Cytosar</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  DepoCyt</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Cytosine Arabinosine</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  5-Azacytidine</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Azacitidine</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  5-aza</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Vidaza</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  5-AZC</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  AZA-CR</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Ladakamycin</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  NSC-102816</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Tosedostat</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;initial_release_date&gt;</div>
<div class="sdl2">  2012-07-06</div>
<div class="sdl1 sdz">&lt;/initial_release_date&gt;</div>
</div><div class="sdl1 sds">&lt;last_release_date&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-f170B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f170&#39;)" style="display:none" /><img id="sdiff-collapse-f170B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f170&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/date&gt;</div>
<div id="sdiff-collapse-f170B-cdiv" class="sdiff-collapsed" title="The middle 383 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f170&#39;)" style="display:none"></div><div id="sdiff-collapse-f170B-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/status_block&gt;</div>
<div class="sdl1 sds">&lt;start_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2012-11</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/start_date&gt;</div>
<div class="sdl1 sda">&lt;primary_compl_date</div>
<div class="sdl1"> type=&quot;Anticipated&quot;</div>
<div class="sdl1">&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2018-11</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/primary_compl_date&gt;</div>
<div class="sdl1 sds">&lt;phase_block&gt;</div>
<div class="sdl2 sds">&lt;phase&gt;</div>
<div class="sdl3">  Phase 1</div>
<div class="sdl2 sdz">&lt;/phase&gt;</div>
<div class="sdl2 sds">&lt;phase&gt;</div>
<div class="sdl3">  Phase 2</div>
<div class="sdl2 sdz">&lt;/phase&gt;</div>
<div class="sdl1 sdz">&lt;/phase_block&gt;</div>
<div class="sdl1 sds">&lt;study_type&gt;</div>
<div class="sdl2">  Interventional</div>
<div class="sdl1 sdz">&lt;/study_type&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Treatment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Randomized</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Open Label</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Single Group Assignment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Safety/Efficacy Study</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;number_of_arms&gt;</div>
<div class="sdl2">  2</div>
<div class="sdl1 sdz">&lt;/number_of_arms&gt;</div>
<div class="sdl1 sds">&lt;primary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Maximum Tolerated Dose (MTD)</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  28 days</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Maximum tolerated daily oral dose defined as &amp;lt;33% of patients experiencing a dose limiting toxicity (DLT) during Cycle 1.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  Yes</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/primary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Anti-Tumor Effects</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  28 days</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Response rate estimated by Bayesian posterior estimates, along with the 95% credible intervals for the two treatment arms. Survival or times to failure and time to progression functions estimated using the Kaplan-Meier method. Toxicity reported by type, frequency and severity. Highest toxicity grades per patient per course tabulated for selected adverse events and laboratory measurements.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  Yes</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sda">&lt;enrollment</div>
<div class="sdl1"> type=&quot;Anticipated&quot;</div>
<div class="sdl1">&gt;</div>
<div class="sdl2">  96</div>
<div class="sdl1 sdz">&lt;/enrollment&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Leukemia</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;arm_group&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Cytarabine + Tosedostat</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_type&gt;</div>
<div class="sdl3">  Experimental</div>
<div class="sdl2 sdz">&lt;/arm_type&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Phase I Arm A: Starting dose of Cytarabine 7.5 mg subcutaneous (SQ) twice daily (BID) for 10 days every 28 days. Dose escalation will proceed up to the Target dose level (dose level 0) 10 mg SQ BID for 10 days.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Phase II (Randomized) Starting dose of Cytarabine: Maximum tolerated dose from Phase I.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Phase I and II Tosedostat: 120 mg by mouth daily. After the first 4 weeks of therapy, a dose escalation to 180 mg daily may be considered for patients not achieving a CR provided the patient has not experienced any grade &amp;gt;/= 3 toxicity. Such instances should be discussed with the principal investigator and the sponsor and assessed on a case-by-case basis.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl1 sdz">&lt;/arm_group&gt;</div>
<div class="sdl1 sds">&lt;arm_group&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  5-Azacytidine + Tosedostat</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_type&gt;</div>
<div class="sdl3">  Experimental</div>
<div class="sdl2 sdz">&lt;/arm_type&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Phase I Arm B: Starting dose of 5-azacytidine 50 mg/m2 by vein (IV) or subcutaneously (SQ) daily for 7 days, on days 1-7 every 28 days. Dose escalation will proceed up to the Target dose level (dose level 0) 75 mg/m2 IV (or SQ) daily for 7 days, on days 1-7.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Phase II (Randomized) Starting dose of 5-azacytidine:  Maximum tolerated dose from Phase I.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Phase I and II Tosedostat: 120 mg by mouth daily. After the first 4 weeks of therapy, a dose escalation to 180 mg daily may be considered for patients not achieving a CR provided the patient has not experienced any grade &amp;gt;/= 3 toxicity. Such instances should be discussed with the principal investigator and the sponsor and assessed on a case-by-case basis.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl1 sdz">&lt;/arm_group&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  Cytarabine</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Phase I Arm A: Starting dose of Cytarabine 7.5 mg subcutaneous (SQ) twice daily (BID) for 10 days every 28 days. Dose escalation will proceed up to the Target dose level (dose level 0) 10 mg SQ BID for 10 days.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Phase II (Randomized) Starting dose of Cytarabine: Maximum tolerated dose from Phase I.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Cytarabine + Tosedostat</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  Ara-C</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  Cytosar</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  DepoCyt</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  Cytosine Arabinosine Hydrochloride</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  5-Azacytidine</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Phase I Arm B: Starting dose of 5-azacytidine 50 mg/m2 by vein (IV) or subcutaneously (SQ) daily for 7 days, on days 1-7 every 28 days. Dose escalation will proceed up to the Target dose level (dose level 0) 75 mg/m2 IV (or SQ) daily for 7 days, on days 1-7.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Phase II (Randomized) Starting dose of 5-azacytidine: Maximum tolerated dose from Phase I.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  5-Azacytidine + Tosedostat</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  Azacitidine</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  5-aza</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  Vidaza</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  5-AZC</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  AZA-CR</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  Ladakamycin</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  NSC-102816</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  Tosedostat</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Phase I: 120 mg by mouth daily.  After the first 4 weeks of therapy, a dose escalation to 180 mg daily may be considered for patients not achieving a CR provided the patient has not experienced any grade &amp;gt;/= 3 toxicity.  Such instances should be discussed with the principal investigator and the sponsor and assessed on a case-by-case basis.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Phase II: 120 mg by mouth daily. 120 mg by mouth daily during induction (i.e., first 28 days of therapy).  After the first 4 weeks of therapy, a dose escalation to 180 mg daily may be considered for patients not achieving a CR provided the patient has not experienced any grade &amp;gt;/= 3 toxicity.  Such instances should be discussed with the principal investigator and the sponsor and assessed on a case-by-case basis.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Cytarabine + Tosedostat</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  5-Azacytidine + Tosedostat</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;eligibility&gt;</div>
<div class="sdl2 sds">&lt;criteria&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Inclusion Criteria:</div>
<div class="sdl4">  </div>
<div class="sdl4">  1)	Signed, informed consent must be obtained prior to any study specific procedures.</div>
<div class="sdl4">  </div>
<div class="sdl4">  2)	For the phase I portion of the study patients should have failed any number of prior therapies, which should include at least the following: 1. Patients with MDS should have failed prior therapy with a hypomethylating agent and/or with lenalidomide. 2. Patients with AML should have failed any prior induction therapy or have relapsed after prior therapy. 3. Patients with MDS who received therapy with a hypomethylating agent and progress to AML are eligible at the time of diagnosis of AML regardless of any prior therapy for AML. 4. Patients with any of the eligible diagnoses who have received no prior therapy are eligible if not candidates to receive standard therapy or if they refuse standard chemotherapy.</div>
<div class="sdl4">  </div>
<div class="sdl4">  3)	For the phase II Portion of the study, only patients who are previously untreated for AML. 1. Patients with history of MDS who received therapy for MDS and progressed to AML are eligible at the time of diagnosis of AML. Only induction chemotherapy administered for AML will be considered for considerations of eligibility regarding prior therapy. Patients who received therapy for MDS before transforming to AML (e.g., with hypomethylating agents or lenalidomide) are eligible.</div>
<div class="sdl4">  </div>
<div class="sdl4">  4)	ECOG performance status of 0-2.</div>
<div class="sdl4">  </div>
<div class="sdl4">  5)	Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must use acceptable contraceptive methods (abstinence, intrauterine device [IUD], oral contraceptive or double barrier device) while on study and must continue to do so for 3 months after stopping study drug, and must have a negative urine or serum pregnancy test within 2 weeks prior to beginning treatment on this trial. Sexually active men must also use acceptable contraceptive methods for the duration of time on study. Pregnant and nursing patients are excluded because the effects of tosedostat on a fetus or nursing child are unknown.</div>
<div class="sdl4">  </div>
<div class="sdl4">  6)	Patients must have been off chemotherapy for 2 weeks prior to entering this study, unless there is evidence of rapidly progressive disease, and must have recovered from the toxic effects of that therapy to at least grade 1. Use of hydroxyurea for patients with rapidly proliferative disease is allowed before the start of study therapy and for the first four weeks on therapy.</div>
<div class="sdl4">  </div>
<div class="sdl4">  7)	Patients must have the following clinical laboratory values unless considered due to leukemic organ involvement: 1. Serum creatinine &amp;lt;/= 2.0 mg/dl. 2. Total bilirubin &amp;lt;/= 1.5x the upper limit of normal unless considered due to Gilbert&amp;apos;s syndrome. 3. Alanine aminotransferase (ALT), or aspartate aminotransferase (AST) &amp;lt;/= 3x the upper limit of normal.</div>
<div class="sdl4">  </div>
<div class="sdl4">  8)	Age &amp;gt;/= 60 years</div>
<div class="sdl4">  </div>
<div class="sdl4">  9)	Left ventricular ejection fraction (LVEF) &amp;gt;/= 50% within 28 days prior to first dose of study drug administration</div>
<div class="sdl4">  </div>
<div class="sdl4">  10)	Patient is able to comply with all study procedures including study drug administration, visits and tests</div>
<div class="sdl4">  </div>
<div class="sdl4">  Exclusion Criteria:</div>
<div class="sdl4">  </div>
<div class="sdl4">  1)	Uncontrolled intercurrent illness including, but not limited to uncontrolled infection, symptomatic congestive heart failure (New York Heart Association Class III or IV), or psychiatric illness/social situations that would limit compliance with study requirements.</div>
<div class="sdl4">  </div>
<div class="sdl4">  2)	Active heart disease including myocardial infarction within previous 3 months, symptomatic coronary artery disease, clinically significant arrhythmias not controlled by medication, or uncontrolled congestive heart failure (New York Heart Association Class III or IV).</div>
<div class="sdl4">  </div>
<div class="sdl4">  3)	Patients with APL (FAB type M3) or CML in blast crisis.</div>
<div class="sdl4">  </div>
<div class="sdl4">  4)	Significant gastrointestinal disorders that may interfere with absorption of tosedostat.</div>
<div class="sdl4">  </div>
<div class="sdl4">  5)	Patients who can receive an allogeneic stem cell transplant within 4 weeks.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/criteria&gt;</div>
<div class="sdl2 sds">&lt;healthy_volunteers&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/healthy_volunteers&gt;</div>
<div class="sdl2 sds">&lt;gender&gt;</div>
<div class="sdl3">  Both</div>
<div class="sdl2 sdz">&lt;/gender&gt;</div>
<div class="sdl2 sds">&lt;minimum_age&gt;</div>
<div class="sdl3">  60 Years</div>
<div class="sdl2 sdz">&lt;/minimum_age&gt;</div>
<div class="sdl2 sds">&lt;maximum_age&gt;</div>
<div class="sdl2 sdz">&lt;/maximum_age&gt;</div>
<div class="sdl1 sdz">&lt;/eligibility&gt;</div>
<div class="sdl1 sds">&lt;investigator&gt;</div>
<div class="sdl2 sds">&lt;role&gt;</div>
<div class="sdl3">  Principal Investigator</div>
<div class="sdl2 sdz">&lt;/role&gt;</div>
<div class="sdl2 sds">&lt;name&gt;</div>
<div class="sdl3">  Jorge Cortes, MD</div>
<div class="sdl2 sdz">&lt;/name&gt;</div>
<div class="sdl2 sds">&lt;affiliation&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  UT MD Anderson Cancer Center</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/affiliation&gt;</div>
<div class="sdl1 sdz">&lt;/investigator&gt;</div>
<div class="sdl1 sds">&lt;contact&gt;</div>
<div class="sdl2 sds">&lt;name&gt;</div>
<div class="sdl3">  Jorge Cortes, MD</div>
<div class="sdl2 sdz">&lt;/name&gt;</div>
<div class="sdl2 sds">&lt;phone&gt;</div>
<div class="sdl3">  713-794-5783</div>
<div class="sdl2 sdz">&lt;/phone&gt;</div>
<div class="sdl2 sds">&lt;phone_ext&gt;</div>
<div class="sdl2 sdz">&lt;/phone_ext&gt;</div>
<div class="sdl2 sds">&lt;email&gt;</div>
<div class="sdl2 sdz">&lt;/email&gt;</div>
<div class="sdl1 sdz">&lt;/contact&gt;</div>
<div class="sdl1 sds">&lt;location&gt;</div>
<div class="sdl2 sds">&lt;facility&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  UT MD Anderson Cancer Center</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl3 sds">&lt;address&gt;</div>
<div class="sdl4 sds">&lt;city&gt;</div>
<div class="sdl5">  Houston</div>
<div class="sdl4 sdz">&lt;/city&gt;</div>
<div class="sdl4 sds">&lt;state&gt;</div>
<div class="sdl5">  Texas</div>
<div class="sdl4 sdz">&lt;/state&gt;</div>
<div class="sdl4 sds">&lt;zip&gt;</div>
<div class="sdl5">  77030</div>
<div class="sdl4 sdz">&lt;/zip&gt;</div>
<div class="sdl4 sds">&lt;country&gt;</div>
<div class="sdl5">  United States</div>
<div class="sdl4 sdz">&lt;/country&gt;</div>
<div class="sdl3 sdz">&lt;/address&gt;</div>
<div class="sdl2 sdz">&lt;/facility&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  Recruiting</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
<div class="sdl1 sdz">&lt;/location&gt;</div>
<div class="sdl1 sds">&lt;see_also&gt;</div>
<div class="sdl2 sds">&lt;annotation&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  UT MD Anderson Cancer Center Website</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/annotation&gt;</div>
<div class="sdl2 sds">&lt;url&gt;</div>
<div class="sdl3">  http://www.mdanderson.org</div>
<div class="sdl2 sdz">&lt;/url&gt;</div>
<div class="sdl1 sdz">&lt;/see_also&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Leukemia</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Acute Myeloid Leukemia</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  AML</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Myelodysplastic Syndromes</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  MDS</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Relapsed</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Refractory</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Cytarabine</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  ARA-C</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Cytosar</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  DepoCyt</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Cytosine Arabinosine</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  5-Azacytidine</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Azacitidine</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  5-aza</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Vidaza</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  5-AZC</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  AZA-CR</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Ladakamycin</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  NSC-102816</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Tosedostat</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;initial_release_date&gt;</div>
<div class="sdl2">  2012-07-06</div>
<div class="sdl1 sdz">&lt;/initial_release_date&gt;</div>
</div><div class="sdl1 sds">&lt;last_release_date&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-f4"><td class="sdiff-h">4</td>
<td class="sdiff-a"><div class="sdl2"><span class="sdwc">2013-03-08</span> </div>
</td>
<td class="sdiff-b"><div class="sdl2"><span class="sdwc">2013-04-24</span> </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-f5"><td class="sdiff-h">5</td>
<td class="sdiff-a"><img id="sdiff-collapse-f556A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f556&#39;)" style="display:none" /><img id="sdiff-collapse-f556A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f556&#39;)" style="display:none" /><div class="sdl1 sdz">&lt;/last_release_date&gt;</div>
<div id="sdiff-collapse-f556A-cdiv" class="sdiff-collapsed" title="The middle 4 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f556&#39;)" style="display:none"></div><div id="sdiff-collapse-f556A-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;init_disposition_release_date&gt;</div>
<div class="sdl1 sdz">&lt;/init_disposition_release_date&gt;</div>
<div class="sdl1 sds">&lt;init_results_release_date&gt;</div>
<div class="sdl1 sdz">&lt;/init_results_release_date&gt;</div>
</div><div class="sdl0 sdz">&lt;/clinical_study&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-f556B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f556&#39;)" style="display:none" /><img id="sdiff-collapse-f556B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f556&#39;)" style="display:none" /><div class="sdl1 sdz">&lt;/last_release_date&gt;</div>
<div id="sdiff-collapse-f556B-cdiv" class="sdiff-collapsed" title="The middle 4 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f556&#39;)" style="display:none"></div><div id="sdiff-collapse-f556B-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;init_disposition_release_date&gt;</div>
<div class="sdl1 sdz">&lt;/init_disposition_release_date&gt;</div>
<div class="sdl1 sds">&lt;init_results_release_date&gt;</div>
<div class="sdl1 sdz">&lt;/init_results_release_date&gt;</div>
</div><div class="sdl0 sdz">&lt;/clinical_study&gt;</div>
</td>
</tr>

</table></div><div class="sdiff-view" id="sdiff-main" style="display: block"><table class="sdiff navLinks"><colgroup><col id="h-col" /><col id="a-col" /><col id="b-col" /></colgroup><tr><th class="sdiff-h" /><th class="sdiff-a"><div class="sdiff-prev"><a href="/archive/NCT01636609/2013_03_08/changes" title="Show changes from prior version to this one"><img src="/archive/prev.gif" alt="[Previous]" width="23" height="19" /></a></div><h2>Before</h2><h3><a href="/archive/NCT01636609/2013_03_08">(Updated 2013_03_08)</a></h3></th><th class="sdiff-b"><div class="sdiff-next"><a href="/archive/NCT01636609/2013_05_02/changes" title="Show changes from this version to next one"><img src="/archive/next.gif" alt="[Next]" width="23" height="19" /></a></div><h2>After</h2><h3><a href="/archive/NCT01636609/2013_04_24">(Updated 2013_04_24)</a></h3></th></tr>
<tr class="sdiff-unc" id="sdiff-chunk-m1"><td class="sdiff-h">1</td>
<td class="sdiff-a"><img id="sdiff-collapse-m0A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none" /><img id="sdiff-collapse-m0A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none" /><div class="sdl0 sds">&lt;clinical_study&gt;</div>
<div id="sdiff-collapse-m0A-cdiv" class="sdiff-collapsed" title="The middle 167 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none"></div><div id="sdiff-collapse-m0A-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;study_id&gt;</div>
<div class="sdl2 sds">&lt;org_name&gt;</div>
<div class="sdl3">  MDAnderson</div>
<div class="sdl2 sdz">&lt;/org_name&gt;</div>
<div class="sdl2 sds">&lt;org_full_name&gt;</div>
<div class="sdl3">  M.D. Anderson Cancer Center</div>
<div class="sdl2 sdz">&lt;/org_full_name&gt;</div>
<div class="sdl2 sds">&lt;org_study_id&gt;</div>
<div class="sdl3">  2011-0188</div>
<div class="sdl2 sdz">&lt;/org_study_id&gt;</div>
<div class="sdl2 sds">&lt;nct_id&gt;</div>
<div class="sdl3">  NCT01636609</div>
<div class="sdl2 sdz">&lt;/nct_id&gt;</div>
<div class="sdl1 sdz">&lt;/study_id&gt;</div>
<div class="sdl1 sds">&lt;is_fda_regulated&gt;</div>
<div class="sdl2">  Yes</div>
<div class="sdl1 sdz">&lt;/is_fda_regulated&gt;</div>
<div class="sdl1 sds">&lt;is_section_801&gt;</div>
<div class="sdl2">  Yes</div>
<div class="sdl1 sdz">&lt;/is_section_801&gt;</div>
<div class="sdl1 sds">&lt;delayed_posting&gt;</div>
<div class="sdl2">  No</div>
<div class="sdl1 sdz">&lt;/delayed_posting&gt;</div>
<div class="sdl1 sds">&lt;brief_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Combination Study of Cytarabine and Tosedostat in Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndromes (MDS)</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_title&gt;</div>
<div class="sdl1 sds">&lt;official_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Phase I/II Study of Cytarabine or 5-Azacitidine Combined With Tosedostat to Evaluate the Safety and Tolerability in Older Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndromes (MDS)</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/official_title&gt;</div>
<div class="sdl1 sds">&lt;study_sponsor&gt;</div>
<div class="sdl2 sds">&lt;lead_sponsor&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  M.D. Anderson Cancer Center</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/lead_sponsor&gt;</div>
<div class="sdl2 sds">&lt;sponsor&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  Cell Therapeutics</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/sponsor&gt;</div>
<div class="sdl1 sdz">&lt;/study_sponsor&gt;</div>
<div class="sdl1 sds">&lt;resp_party&gt;</div>
<div class="sdl2 sds">&lt;resp_party_type&gt;</div>
<div class="sdl3">  Sponsor</div>
<div class="sdl2 sdz">&lt;/resp_party_type&gt;</div>
<div class="sdl1 sdz">&lt;/resp_party&gt;</div>
<div class="sdl1 sds">&lt;oversight_info&gt;</div>
<div class="sdl2 sds">&lt;regulatory_authority&gt;</div>
<div class="sdl3">  United States: Food and Drug Administration</div>
<div class="sdl2 sdz">&lt;/regulatory_authority&gt;</div>
<div class="sdl2 sds">&lt;has_dmc&gt;</div>
<div class="sdl3">  Yes</div>
<div class="sdl2 sdz">&lt;/has_dmc&gt;</div>
<div class="sdl1 sdz">&lt;/oversight_info&gt;</div>
<div class="sdl1 sds">&lt;brief_summary&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  The goal of the Phase 1 part of this clinical research study is to learn the highest tolerable dose of cytarabine that can be given with tosedostat and the highest tolerable dose of  5-azacitidine that can be given with tosedostat to patients with AML or MDS.</div>
<div class="sdl3">  </div>
<div class="sdl3">  The goal of the Phase 2 part of the study is to learn if cytarabine with tosedostat and/or 5-azacitidine with tosedostat can help to control the disease.  The safety of these combinations will continue to be studied.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Tosedostat is designed to block the production of proteins that cancer cells need to grow.  Blocking these proteins may cause the cancer cells to die.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Cytarabine is designed to insert itself into DNA (genetic material) of cancer cells and stop the DNA from repairing itself.</div>
<div class="sdl3">  </div>
<div class="sdl3">  5-azacitidine is designed to block certain proteins in cancer cells whose job is to stop the function of the tumor-fighting proteins.  By blocking these proteins, the tumor-fighting genes may be able to work better.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_summary&gt;</div>
<div class="sdl1 sds">&lt;detailed_descr&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Study Groups:</div>
<div class="sdl3">  If you are found to be eligible to take part in this study, you will be assigned to receive cytarabine with tosedostat (Group 1) or 5-azacitidine (Group 2). Your doctor will decide which drugs you will receive.</div>
<div class="sdl3">  </div>
<div class="sdl3">  You will be assigned to a study phase based on when you join this study.  Up to 2 groups of about 18 participants will be enrolled in the Phase I portion of the study, and up to 60 participants will be enrolled in Phase II.</div>
<div class="sdl3">  </div>
<div class="sdl3">  If you are enrolled in the Phase I portion, the dose of cytarabine or 5-azacitidine you receive will depend on when you joined this study.  The first group of participants will receive the lowest dose level of cytarabine or 5-azacitidine.  The second group will receive a higher dose of cytarabine or 5-azacitidine than the group before it, if no intolerable side effects were seen.  </div>
<div class="sdl3">  </div>
<div class="sdl3">  If you are enrolled in the Phase II portion, you will receive cytarabine or 5-azacitidine at the highest dose that was tolerated in the Phase I portion.</div>
<div class="sdl3">  </div>
<div class="sdl3">  All participants will receive the same dose level of tosedostat.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Study Drug Administration:</div>
<div class="sdl3">  In this study you receive induction therapy to try to control the disease and cause remission (the point when tests and/or your doctor cannot find signs of the disease).  If the disease is in remission, you may receive more cycles (called Consolidation Cycles) to help keep the disease under control.  </div>
<div class="sdl3">  </div>
<div class="sdl3">  Each study cycle is about 4 weeks long, but may be longer depending on your response to the study drug(s). </div>
<div class="sdl3">  </div>
<div class="sdl3">  Participants in both groups will take tosedostat by mouth 1 time every day.   You should take the pills at about the same time every day (about 24 hours between doses) during a meal or just after a meal.  You may take the drug with water.  </div>
<div class="sdl3">  </div>
<div class="sdl3">  You will be given a study drug diary, so you can record when you take each dose. You should complete this diary every day and bring it with you to all study visits. You should also bring any unused tosedostat to each study visit including all empty pots.</div>
<div class="sdl3">  </div>
<div class="sdl3">  You should not take more than your assigned number of capsules within a 24-hour period.  If you accidentally take more on 1 day, you should tell your study doctor right away. If you miss a dose in the morning then you can take the dose up until late afternoon (5pm). After that time the dose should be omitted and you should continue your drug schedule as usual the following day.  Do not try to &amp;quot;make up&amp;quot; the missed dose after 5pm.</div>
<div class="sdl3">  </div>
<div class="sdl3">  If you are in Group 1, you will also receive cytarabine by a needle under the skin 2 times each day on Days 1-10.  </div>
<div class="sdl3">  </div>
<div class="sdl3">  If you are in Group 2, you will also receive 5-azacitidine by vein over 10-40 minutes or by a needle under the skin each day on Days 1-7.  </div>
<div class="sdl3">  </div>
<div class="sdl3">  After induction, the amount of tosedostat you receive may be increased. Your doctor may decide to stop the cytarabine or 5-azacitidine and continue with tosedostat alone.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Study Visits:</div>
<div class="sdl3">  On Day 1 of Cycle 1:</div>
<div class="sdl3">  -You will have a physical exam, including measurement of your vital signs.</div>
<div class="sdl3">  -Blood (about 1 teaspoon) will be drawn for routine tests.</div>
<div class="sdl3">  -Blood (about 1 teaspoon) will be drawn for pharmacokinetic (PK) testing.  PK testing measures the amount of study drug in your body at different time points.</div>
<div class="sdl3">  -Your performance status will be recorded.</div>
<div class="sdl3">  -Your medical history will be recorded.</div>
<div class="sdl3">  -You will be asked about any drugs you may be taking.</div>
<div class="sdl3">  </div>
<div class="sdl3">  On Days 8, 15, and 22 of Cycle 1 (+/- 2 days):</div>
<div class="sdl3">  -Your vital signs will be measured.</div>
<div class="sdl3">  -Blood (about 1 teaspoon) will be drawn for routine tests.</div>
<div class="sdl3">  -You will have an ECG.</div>
<div class="sdl3">  -You will be asked about any drugs you may be taking and side effects you may be having.</div>
<div class="sdl3">  -On Day 8 only, you will have a physical exam.</div>
<div class="sdl3">  -On Day 15 only, blood (about 1 teaspoon) will be drawn for PK testing.</div>
<div class="sdl3">  </div>
<div class="sdl3">  On Day 28 of Cycle 1 (+/- 5 days) (this visit may be combined with the Day 1 of Cycle 2 visit):</div>
<div class="sdl3">  -You will have a physical exam, including measurement of your vital signs.</div>
<div class="sdl3">  -Blood (about 1 teaspoon) will be drawn for routine tests.</div>
<div class="sdl3">  -Blood (about 1 teaspoon) will be drawn for PK testing.</div>
<div class="sdl3">  -Your performance status will be recorded.</div>
<div class="sdl3">  -You will be asked about any drugs you may be taking and side effects you may be having.</div>
<div class="sdl3">  -You will have an ECG.</div>
<div class="sdl3">  -You will have a bone marrow biopsy/aspiration to check the status of the disease.</div>
<div class="sdl3">  </div>
<div class="sdl3">  On Day 1 of Cycles 2 and beyond (+/- 5 days):</div>
<div class="sdl3">  -You will have a physical exam, including measurement of your vital signs.</div>
<div class="sdl3">  -Blood (about 1 teaspoon) will be drawn for routine tests.</div>
<div class="sdl3">  -Your performance status will be recorded.</div>
<div class="sdl3">  -You will be asked about any drugs you may be taking and side effects you may be having.</div>
<div class="sdl3">  -You will have an ECG.</div>
<div class="sdl3">  -During Cycles 2 and 3 only, blood (about 1 teaspoon) will be drawn for PK testing.</div>
<div class="sdl3">  -During odd-numbered cycles (3, 5, 7 and so on), you will have a bone marrow biopsy/aspiration to check the status of the disease.</div>
<div class="sdl3">  </div>
<div class="sdl3">  If your study doctor feels it is needed, you may have extra clinic visits, tests, or procedures. </div>
<div class="sdl3">  </div>
<div class="sdl3">  Participants Receiving Home Care:</div>
<div class="sdl3">  If you will receive the first cycle at home, you will be called on Day 14 (+/- 5 days) of Cycle 1 and asked about any side effects you may be having. This call will take about 15 minutes.</div>
<div class="sdl3">  </div>
<div class="sdl3">  If you are receiving home care, you will return to MD Anderson before the start of each cycle During Cycles 1-3, then every 3 cycles (+/- 1 cycle) until 1 year after the start of therapy, and then every 6 months (+/- 1 month) after that.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Length of Study:</div>
<div class="sdl3">  You may take the study drug for up to 1 year. You will be taken off study early if the disease gets worse, if you have intolerable side effects, if you are not able to follow the study directions, or if the study doctor thinks it is in your best interest.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Your participation on the study will be over once you have completed the follow-up.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Follow-Up:</div>
<div class="sdl3">  About 28 days after your last dose of tosedostat:</div>
<div class="sdl3">  -You will have a physical exam, including measurement of your vital signs.</div>
<div class="sdl3">  -Your performance status will be recorded.</div>
<div class="sdl3">  -Blood (about 1 teaspoon) will be drawn for routine tests.</div>
<div class="sdl3">  -You will have an ECG. </div>
<div class="sdl3">  -You will be asked about any side effect that you may have had and any drugs you may be taking. </div>
<div class="sdl3">  </div>
<div class="sdl3">  Once you have completed the follow-up visit, the study staff may contact you by telephone every 3-6 months to check the status of your health.  Keeping in touch with you and checking on your condition will help researchers look at the long-term effects of the study drug.</div>
<div class="sdl3">  </div>
<div class="sdl3">  This is an investigational study.  Tosedostat is not FDA approved or commercially available.  At this time, tosedostat is only being used in research. Cytarabine is FDA approved and commercially available for certain types of MDS and AML. 5-azacitidine is FDA approved and commercially available for certain types of MDS and AML. </div>
<div class="sdl3">  </div>
<div class="sdl3">  Up to 96 patients will take part in this study. All patients will be enrolled at MD Anderson.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/detailed_descr&gt;</div>
<div class="sdl1 sds">&lt;status_block&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  Recruiting</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
</div><div class="sdl2 sds">&lt;date&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-m0B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none" /><img id="sdiff-collapse-m0B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none" /><div class="sdl0 sds">&lt;clinical_study&gt;</div>
<div id="sdiff-collapse-m0B-cdiv" class="sdiff-collapsed" title="The middle 167 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none"></div><div id="sdiff-collapse-m0B-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;study_id&gt;</div>
<div class="sdl2 sds">&lt;org_name&gt;</div>
<div class="sdl3">  MDAnderson</div>
<div class="sdl2 sdz">&lt;/org_name&gt;</div>
<div class="sdl2 sds">&lt;org_full_name&gt;</div>
<div class="sdl3">  M.D. Anderson Cancer Center</div>
<div class="sdl2 sdz">&lt;/org_full_name&gt;</div>
<div class="sdl2 sds">&lt;org_study_id&gt;</div>
<div class="sdl3">  2011-0188</div>
<div class="sdl2 sdz">&lt;/org_study_id&gt;</div>
<div class="sdl2 sds">&lt;nct_id&gt;</div>
<div class="sdl3">  NCT01636609</div>
<div class="sdl2 sdz">&lt;/nct_id&gt;</div>
<div class="sdl1 sdz">&lt;/study_id&gt;</div>
<div class="sdl1 sds">&lt;is_fda_regulated&gt;</div>
<div class="sdl2">  Yes</div>
<div class="sdl1 sdz">&lt;/is_fda_regulated&gt;</div>
<div class="sdl1 sds">&lt;is_section_801&gt;</div>
<div class="sdl2">  Yes</div>
<div class="sdl1 sdz">&lt;/is_section_801&gt;</div>
<div class="sdl1 sds">&lt;delayed_posting&gt;</div>
<div class="sdl2">  No</div>
<div class="sdl1 sdz">&lt;/delayed_posting&gt;</div>
<div class="sdl1 sds">&lt;brief_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Combination Study of Cytarabine and Tosedostat in Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndromes (MDS)</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_title&gt;</div>
<div class="sdl1 sds">&lt;official_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Phase I/II Study of Cytarabine or 5-Azacitidine Combined With Tosedostat to Evaluate the Safety and Tolerability in Older Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndromes (MDS)</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/official_title&gt;</div>
<div class="sdl1 sds">&lt;study_sponsor&gt;</div>
<div class="sdl2 sds">&lt;lead_sponsor&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  M.D. Anderson Cancer Center</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/lead_sponsor&gt;</div>
<div class="sdl2 sds">&lt;sponsor&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  Cell Therapeutics</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/sponsor&gt;</div>
<div class="sdl1 sdz">&lt;/study_sponsor&gt;</div>
<div class="sdl1 sds">&lt;resp_party&gt;</div>
<div class="sdl2 sds">&lt;resp_party_type&gt;</div>
<div class="sdl3">  Sponsor</div>
<div class="sdl2 sdz">&lt;/resp_party_type&gt;</div>
<div class="sdl1 sdz">&lt;/resp_party&gt;</div>
<div class="sdl1 sds">&lt;oversight_info&gt;</div>
<div class="sdl2 sds">&lt;regulatory_authority&gt;</div>
<div class="sdl3">  United States: Food and Drug Administration</div>
<div class="sdl2 sdz">&lt;/regulatory_authority&gt;</div>
<div class="sdl2 sds">&lt;has_dmc&gt;</div>
<div class="sdl3">  Yes</div>
<div class="sdl2 sdz">&lt;/has_dmc&gt;</div>
<div class="sdl1 sdz">&lt;/oversight_info&gt;</div>
<div class="sdl1 sds">&lt;brief_summary&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  The goal of the Phase 1 part of this clinical research study is to learn the highest tolerable dose of cytarabine that can be given with tosedostat and the highest tolerable dose of  5-azacitidine that can be given with tosedostat to patients with AML or MDS.</div>
<div class="sdl3">  </div>
<div class="sdl3">  The goal of the Phase 2 part of the study is to learn if cytarabine with tosedostat and/or 5-azacitidine with tosedostat can help to control the disease.  The safety of these combinations will continue to be studied.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Tosedostat is designed to block the production of proteins that cancer cells need to grow.  Blocking these proteins may cause the cancer cells to die.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Cytarabine is designed to insert itself into DNA (genetic material) of cancer cells and stop the DNA from repairing itself.</div>
<div class="sdl3">  </div>
<div class="sdl3">  5-azacitidine is designed to block certain proteins in cancer cells whose job is to stop the function of the tumor-fighting proteins.  By blocking these proteins, the tumor-fighting genes may be able to work better.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_summary&gt;</div>
<div class="sdl1 sds">&lt;detailed_descr&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Study Groups:</div>
<div class="sdl3">  If you are found to be eligible to take part in this study, you will be assigned to receive cytarabine with tosedostat (Group 1) or 5-azacitidine (Group 2). Your doctor will decide which drugs you will receive.</div>
<div class="sdl3">  </div>
<div class="sdl3">  You will be assigned to a study phase based on when you join this study.  Up to 2 groups of about 18 participants will be enrolled in the Phase I portion of the study, and up to 60 participants will be enrolled in Phase II.</div>
<div class="sdl3">  </div>
<div class="sdl3">  If you are enrolled in the Phase I portion, the dose of cytarabine or 5-azacitidine you receive will depend on when you joined this study.  The first group of participants will receive the lowest dose level of cytarabine or 5-azacitidine.  The second group will receive a higher dose of cytarabine or 5-azacitidine than the group before it, if no intolerable side effects were seen.  </div>
<div class="sdl3">  </div>
<div class="sdl3">  If you are enrolled in the Phase II portion, you will receive cytarabine or 5-azacitidine at the highest dose that was tolerated in the Phase I portion.</div>
<div class="sdl3">  </div>
<div class="sdl3">  All participants will receive the same dose level of tosedostat.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Study Drug Administration:</div>
<div class="sdl3">  In this study you receive induction therapy to try to control the disease and cause remission (the point when tests and/or your doctor cannot find signs of the disease).  If the disease is in remission, you may receive more cycles (called Consolidation Cycles) to help keep the disease under control.  </div>
<div class="sdl3">  </div>
<div class="sdl3">  Each study cycle is about 4 weeks long, but may be longer depending on your response to the study drug(s). </div>
<div class="sdl3">  </div>
<div class="sdl3">  Participants in both groups will take tosedostat by mouth 1 time every day.   You should take the pills at about the same time every day (about 24 hours between doses) during a meal or just after a meal.  You may take the drug with water.  </div>
<div class="sdl3">  </div>
<div class="sdl3">  You will be given a study drug diary, so you can record when you take each dose. You should complete this diary every day and bring it with you to all study visits. You should also bring any unused tosedostat to each study visit including all empty pots.</div>
<div class="sdl3">  </div>
<div class="sdl3">  You should not take more than your assigned number of capsules within a 24-hour period.  If you accidentally take more on 1 day, you should tell your study doctor right away. If you miss a dose in the morning then you can take the dose up until late afternoon (5pm). After that time the dose should be omitted and you should continue your drug schedule as usual the following day.  Do not try to &amp;quot;make up&amp;quot; the missed dose after 5pm.</div>
<div class="sdl3">  </div>
<div class="sdl3">  If you are in Group 1, you will also receive cytarabine by a needle under the skin 2 times each day on Days 1-10.  </div>
<div class="sdl3">  </div>
<div class="sdl3">  If you are in Group 2, you will also receive 5-azacitidine by vein over 10-40 minutes or by a needle under the skin each day on Days 1-7.  </div>
<div class="sdl3">  </div>
<div class="sdl3">  After induction, the amount of tosedostat you receive may be increased. Your doctor may decide to stop the cytarabine or 5-azacitidine and continue with tosedostat alone.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Study Visits:</div>
<div class="sdl3">  On Day 1 of Cycle 1:</div>
<div class="sdl3">  -You will have a physical exam, including measurement of your vital signs.</div>
<div class="sdl3">  -Blood (about 1 teaspoon) will be drawn for routine tests.</div>
<div class="sdl3">  -Blood (about 1 teaspoon) will be drawn for pharmacokinetic (PK) testing.  PK testing measures the amount of study drug in your body at different time points.</div>
<div class="sdl3">  -Your performance status will be recorded.</div>
<div class="sdl3">  -Your medical history will be recorded.</div>
<div class="sdl3">  -You will be asked about any drugs you may be taking.</div>
<div class="sdl3">  </div>
<div class="sdl3">  On Days 8, 15, and 22 of Cycle 1 (+/- 2 days):</div>
<div class="sdl3">  -Your vital signs will be measured.</div>
<div class="sdl3">  -Blood (about 1 teaspoon) will be drawn for routine tests.</div>
<div class="sdl3">  -You will have an ECG.</div>
<div class="sdl3">  -You will be asked about any drugs you may be taking and side effects you may be having.</div>
<div class="sdl3">  -On Day 8 only, you will have a physical exam.</div>
<div class="sdl3">  -On Day 15 only, blood (about 1 teaspoon) will be drawn for PK testing.</div>
<div class="sdl3">  </div>
<div class="sdl3">  On Day 28 of Cycle 1 (+/- 5 days) (this visit may be combined with the Day 1 of Cycle 2 visit):</div>
<div class="sdl3">  -You will have a physical exam, including measurement of your vital signs.</div>
<div class="sdl3">  -Blood (about 1 teaspoon) will be drawn for routine tests.</div>
<div class="sdl3">  -Blood (about 1 teaspoon) will be drawn for PK testing.</div>
<div class="sdl3">  -Your performance status will be recorded.</div>
<div class="sdl3">  -You will be asked about any drugs you may be taking and side effects you may be having.</div>
<div class="sdl3">  -You will have an ECG.</div>
<div class="sdl3">  -You will have a bone marrow biopsy/aspiration to check the status of the disease.</div>
<div class="sdl3">  </div>
<div class="sdl3">  On Day 1 of Cycles 2 and beyond (+/- 5 days):</div>
<div class="sdl3">  -You will have a physical exam, including measurement of your vital signs.</div>
<div class="sdl3">  -Blood (about 1 teaspoon) will be drawn for routine tests.</div>
<div class="sdl3">  -Your performance status will be recorded.</div>
<div class="sdl3">  -You will be asked about any drugs you may be taking and side effects you may be having.</div>
<div class="sdl3">  -You will have an ECG.</div>
<div class="sdl3">  -During Cycles 2 and 3 only, blood (about 1 teaspoon) will be drawn for PK testing.</div>
<div class="sdl3">  -During odd-numbered cycles (3, 5, 7 and so on), you will have a bone marrow biopsy/aspiration to check the status of the disease.</div>
<div class="sdl3">  </div>
<div class="sdl3">  If your study doctor feels it is needed, you may have extra clinic visits, tests, or procedures. </div>
<div class="sdl3">  </div>
<div class="sdl3">  Participants Receiving Home Care:</div>
<div class="sdl3">  If you will receive the first cycle at home, you will be called on Day 14 (+/- 5 days) of Cycle 1 and asked about any side effects you may be having. This call will take about 15 minutes.</div>
<div class="sdl3">  </div>
<div class="sdl3">  If you are receiving home care, you will return to MD Anderson before the start of each cycle During Cycles 1-3, then every 3 cycles (+/- 1 cycle) until 1 year after the start of therapy, and then every 6 months (+/- 1 month) after that.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Length of Study:</div>
<div class="sdl3">  You may take the study drug for up to 1 year. You will be taken off study early if the disease gets worse, if you have intolerable side effects, if you are not able to follow the study directions, or if the study doctor thinks it is in your best interest.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Your participation on the study will be over once you have completed the follow-up.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Follow-Up:</div>
<div class="sdl3">  About 28 days after your last dose of tosedostat:</div>
<div class="sdl3">  -You will have a physical exam, including measurement of your vital signs.</div>
<div class="sdl3">  -Your performance status will be recorded.</div>
<div class="sdl3">  -Blood (about 1 teaspoon) will be drawn for routine tests.</div>
<div class="sdl3">  -You will have an ECG. </div>
<div class="sdl3">  -You will be asked about any side effect that you may have had and any drugs you may be taking. </div>
<div class="sdl3">  </div>
<div class="sdl3">  Once you have completed the follow-up visit, the study staff may contact you by telephone every 3-6 months to check the status of your health.  Keeping in touch with you and checking on your condition will help researchers look at the long-term effects of the study drug.</div>
<div class="sdl3">  </div>
<div class="sdl3">  This is an investigational study.  Tosedostat is not FDA approved or commercially available.  At this time, tosedostat is only being used in research. Cytarabine is FDA approved and commercially available for certain types of MDS and AML. 5-azacitidine is FDA approved and commercially available for certain types of MDS and AML. </div>
<div class="sdl3">  </div>
<div class="sdl3">  Up to 96 patients will take part in this study. All patients will be enrolled at MD Anderson.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/detailed_descr&gt;</div>
<div class="sdl1 sds">&lt;status_block&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  Recruiting</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
</div><div class="sdl2 sds">&lt;date&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-m2"><td class="sdiff-h">2</td>
<td class="sdiff-a"><div class="sdl3"><span class="sdwc">2013-03</span> </div>
</td>
<td class="sdiff-b"><div class="sdl3"><span class="sdwc">2013-04</span> </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-m3"><td class="sdiff-h">3</td>
<td class="sdiff-a"><img id="sdiff-collapse-m170A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m170&#39;)" style="display:none" /><img id="sdiff-collapse-m170A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m170&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/date&gt;</div>
<div id="sdiff-collapse-m170A-cdiv" class="sdiff-collapsed" title="The middle 347 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m170&#39;)" style="display:none"></div><div id="sdiff-collapse-m170A-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/status_block&gt;</div>
<div class="sdl1 sds">&lt;start_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2012-11</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/start_date&gt;</div>
<div class="sdl1 sda">&lt;primary_compl_date</div>
<div class="sdl1"> type=&quot;Anticipated&quot;</div>
<div class="sdl1">&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2018-11</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/primary_compl_date&gt;</div>
<div class="sdl1 sds">&lt;phase_block&gt;</div>
<div class="sdl2 sds">&lt;phase&gt;</div>
<div class="sdl3">  Phase 1</div>
<div class="sdl2 sdz">&lt;/phase&gt;</div>
<div class="sdl2 sds">&lt;phase&gt;</div>
<div class="sdl3">  Phase 2</div>
<div class="sdl2 sdz">&lt;/phase&gt;</div>
<div class="sdl1 sdz">&lt;/phase_block&gt;</div>
<div class="sdl1 sds">&lt;study_type&gt;</div>
<div class="sdl2">  Interventional</div>
<div class="sdl1 sdz">&lt;/study_type&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Treatment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Randomized</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Open Label</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Single Group Assignment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Safety/Efficacy Study</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;number_of_arms&gt;</div>
<div class="sdl2">  2</div>
<div class="sdl1 sdz">&lt;/number_of_arms&gt;</div>
<div class="sdl1 sds">&lt;primary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Maximum Tolerated Dose (MTD)</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  28 days</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Maximum tolerated daily oral dose defined as &amp;lt;33% of patients experiencing a dose limiting toxicity (DLT) during Cycle 1.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  Yes</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/primary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Anti-Tumor Effects</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  28 days</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Response rate estimated by Bayesian posterior estimates, along with the 95% credible intervals for the two treatment arms. Survival or times to failure and time to progression functions estimated using the Kaplan-Meier method. Toxicity reported by type, frequency and severity. Highest toxicity grades per patient per course tabulated for selected adverse events and laboratory measurements.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  Yes</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sda">&lt;enrollment</div>
<div class="sdl1"> type=&quot;Anticipated&quot;</div>
<div class="sdl1">&gt;</div>
<div class="sdl2">  96</div>
<div class="sdl1 sdz">&lt;/enrollment&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Leukemia</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;arm_group&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Cytarabine + Tosedostat</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_type&gt;</div>
<div class="sdl3">  Experimental</div>
<div class="sdl2 sdz">&lt;/arm_type&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Phase I Arm A: Starting dose of Cytarabine 7.5 mg subcutaneous (SQ) twice daily (BID) for 10 days every 28 days. Dose escalation will proceed up to the Target dose level (dose level 0) 10 mg SQ BID for 10 days.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Phase II (Randomized) Starting dose of Cytarabine: Maximum tolerated dose from Phase I.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Phase I and II Tosedostat: 120 mg by mouth daily. After the first 4 weeks of therapy, a dose escalation to 180 mg daily may be considered for patients not achieving a CR provided the patient has not experienced any grade &amp;gt;/= 3 toxicity. Such instances should be discussed with the principal investigator and the sponsor and assessed on a case-by-case basis.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl1 sdz">&lt;/arm_group&gt;</div>
<div class="sdl1 sds">&lt;arm_group&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  5-Azacytidine + Tosedostat</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_type&gt;</div>
<div class="sdl3">  Experimental</div>
<div class="sdl2 sdz">&lt;/arm_type&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Phase I Arm B: Starting dose of 5-azacytidine 50 mg/m2 by vein (IV) or subcutaneously (SQ) daily for 7 days, on days 1-7 every 28 days. Dose escalation will proceed up to the Target dose level (dose level 0) 75 mg/m2 IV (or SQ) daily for 7 days, on days 1-7.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Phase II (Randomized) Starting dose of 5-azacytidine:  Maximum tolerated dose from Phase I.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Phase I and II Tosedostat: 120 mg by mouth daily. After the first 4 weeks of therapy, a dose escalation to 180 mg daily may be considered for patients not achieving a CR provided the patient has not experienced any grade &amp;gt;/= 3 toxicity. Such instances should be discussed with the principal investigator and the sponsor and assessed on a case-by-case basis.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl1 sdz">&lt;/arm_group&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  Cytarabine</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Phase I Arm A: Starting dose of Cytarabine 7.5 mg subcutaneous (SQ) twice daily (BID) for 10 days every 28 days. Dose escalation will proceed up to the Target dose level (dose level 0) 10 mg SQ BID for 10 days.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Phase II (Randomized) Starting dose of Cytarabine: Maximum tolerated dose from Phase I.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Cytarabine + Tosedostat</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  Ara-C</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  Cytosar</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  DepoCyt</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  Cytosine Arabinosine Hydrochloride</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  5-Azacytidine</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Phase I Arm B: Starting dose of 5-azacytidine 50 mg/m2 by vein (IV) or subcutaneously (SQ) daily for 7 days, on days 1-7 every 28 days. Dose escalation will proceed up to the Target dose level (dose level 0) 75 mg/m2 IV (or SQ) daily for 7 days, on days 1-7.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Phase II (Randomized) Starting dose of 5-azacytidine: Maximum tolerated dose from Phase I.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  5-Azacytidine + Tosedostat</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  Azacitidine</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  5-aza</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  Vidaza</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  5-AZC</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  AZA-CR</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  Ladakamycin</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  NSC-102816</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  Tosedostat</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Phase I: 120 mg by mouth daily.  After the first 4 weeks of therapy, a dose escalation to 180 mg daily may be considered for patients not achieving a CR provided the patient has not experienced any grade &amp;gt;/= 3 toxicity.  Such instances should be discussed with the principal investigator and the sponsor and assessed on a case-by-case basis.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Phase II: 120 mg by mouth daily. 120 mg by mouth daily during induction (i.e., first 28 days of therapy).  After the first 4 weeks of therapy, a dose escalation to 180 mg daily may be considered for patients not achieving a CR provided the patient has not experienced any grade &amp;gt;/= 3 toxicity.  Such instances should be discussed with the principal investigator and the sponsor and assessed on a case-by-case basis.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Cytarabine + Tosedostat</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  5-Azacytidine + Tosedostat</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;eligibility&gt;</div>
<div class="sdl2 sds">&lt;criteria&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Inclusion Criteria:</div>
<div class="sdl4">  </div>
<div class="sdl4">  1)	Signed, informed consent must be obtained prior to any study specific procedures.</div>
<div class="sdl4">  </div>
<div class="sdl4">  2)	For the phase I portion of the study patients should have failed any number of prior therapies, which should include at least the following: 1. Patients with MDS should have failed prior therapy with a hypomethylating agent and/or with lenalidomide. 2. Patients with AML should have failed any prior induction therapy or have relapsed after prior therapy. 3. Patients with MDS who received therapy with a hypomethylating agent and progress to AML are eligible at the time of diagnosis of AML regardless of any prior therapy for AML. 4. Patients with any of the eligible diagnoses who have received no prior therapy are eligible if not candidates to receive standard therapy or if they refuse standard chemotherapy.</div>
<div class="sdl4">  </div>
<div class="sdl4">  3)	For the phase II Portion of the study, only patients who are previously untreated for AML. 1. Patients with history of MDS who received therapy for MDS and progressed to AML are eligible at the time of diagnosis of AML. Only induction chemotherapy administered for AML will be considered for considerations of eligibility regarding prior therapy. Patients who received therapy for MDS before transforming to AML (e.g., with hypomethylating agents or lenalidomide) are eligible.</div>
<div class="sdl4">  </div>
<div class="sdl4">  4)	ECOG performance status of 0-2.</div>
<div class="sdl4">  </div>
<div class="sdl4">  5)	Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must use acceptable contraceptive methods (abstinence, intrauterine device [IUD], oral contraceptive or double barrier device) while on study and must continue to do so for 3 months after stopping study drug, and must have a negative urine or serum pregnancy test within 2 weeks prior to beginning treatment on this trial. Sexually active men must also use acceptable contraceptive methods for the duration of time on study. Pregnant and nursing patients are excluded because the effects of tosedostat on a fetus or nursing child are unknown.</div>
<div class="sdl4">  </div>
<div class="sdl4">  6)	Patients must have been off chemotherapy for 2 weeks prior to entering this study, unless there is evidence of rapidly progressive disease, and must have recovered from the toxic effects of that therapy to at least grade 1. Use of hydroxyurea for patients with rapidly proliferative disease is allowed before the start of study therapy and for the first four weeks on therapy.</div>
<div class="sdl4">  </div>
<div class="sdl4">  7)	Patients must have the following clinical laboratory values unless considered due to leukemic organ involvement: 1. Serum creatinine &amp;lt;/= 2.0 mg/dl. 2. Total bilirubin &amp;lt;/= 1.5x the upper limit of normal unless considered due to Gilbert&amp;apos;s syndrome. 3. Alanine aminotransferase (ALT), or aspartate aminotransferase (AST) &amp;lt;/= 3x the upper limit of normal.</div>
<div class="sdl4">  </div>
<div class="sdl4">  8)	Age &amp;gt;/= 60 years</div>
<div class="sdl4">  </div>
<div class="sdl4">  9)	Left ventricular ejection fraction (LVEF) &amp;gt;/= 50% within 28 days prior to first dose of study drug administration</div>
<div class="sdl4">  </div>
<div class="sdl4">  10)	Patient is able to comply with all study procedures including study drug administration, visits and tests</div>
<div class="sdl4">  </div>
<div class="sdl4">  Exclusion Criteria:</div>
<div class="sdl4">  </div>
<div class="sdl4">  1)	Uncontrolled intercurrent illness including, but not limited to uncontrolled infection, symptomatic congestive heart failure (New York Heart Association Class III or IV), or psychiatric illness/social situations that would limit compliance with study requirements.</div>
<div class="sdl4">  </div>
<div class="sdl4">  2)	Active heart disease including myocardial infarction within previous 3 months, symptomatic coronary artery disease, clinically significant arrhythmias not controlled by medication, or uncontrolled congestive heart failure (New York Heart Association Class III or IV).</div>
<div class="sdl4">  </div>
<div class="sdl4">  3)	Patients with APL (FAB type M3) or CML in blast crisis.</div>
<div class="sdl4">  </div>
<div class="sdl4">  4)	Significant gastrointestinal disorders that may interfere with absorption of tosedostat.</div>
<div class="sdl4">  </div>
<div class="sdl4">  5)	Patients who can receive an allogeneic stem cell transplant within 4 weeks.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/criteria&gt;</div>
<div class="sdl2 sds">&lt;healthy_volunteers&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/healthy_volunteers&gt;</div>
<div class="sdl2 sds">&lt;gender&gt;</div>
<div class="sdl3">  Both</div>
<div class="sdl2 sdz">&lt;/gender&gt;</div>
<div class="sdl2 sds">&lt;minimum_age&gt;</div>
<div class="sdl3">  60 Years</div>
<div class="sdl2 sdz">&lt;/minimum_age&gt;</div>
<div class="sdl2 sds">&lt;maximum_age&gt;</div>
<div class="sdl2 sdz">&lt;/maximum_age&gt;</div>
<div class="sdl1 sdz">&lt;/eligibility&gt;</div>
<div class="sdl1 sds">&lt;investigator&gt;</div>
<div class="sdl2 sds">&lt;role&gt;</div>
<div class="sdl3">  Principal Investigator</div>
<div class="sdl2 sdz">&lt;/role&gt;</div>
<div class="sdl2 sds">&lt;name&gt;</div>
<div class="sdl3">  Jorge Cortes, MD</div>
<div class="sdl2 sdz">&lt;/name&gt;</div>
<div class="sdl2 sds">&lt;affiliation&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  UT MD Anderson Cancer Center</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/affiliation&gt;</div>
<div class="sdl1 sdz">&lt;/investigator&gt;</div>
<div class="sdl1 sds">&lt;see_also&gt;</div>
<div class="sdl2 sds">&lt;annotation&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  UT MD Anderson Cancer Center Website</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/annotation&gt;</div>
<div class="sdl2 sds">&lt;url&gt;</div>
<div class="sdl3">  http://www.mdanderson.org</div>
<div class="sdl2 sdz">&lt;/url&gt;</div>
<div class="sdl1 sdz">&lt;/see_also&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Leukemia</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Acute Myeloid Leukemia</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  AML</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Myelodysplastic Syndromes</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  MDS</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Relapsed</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Refractory</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Cytarabine</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  ARA-C</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Cytosar</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  DepoCyt</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Cytosine Arabinosine</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  5-Azacytidine</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Azacitidine</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  5-aza</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Vidaza</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  5-AZC</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  AZA-CR</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Ladakamycin</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  NSC-102816</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Tosedostat</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;initial_release_date&gt;</div>
<div class="sdl2">  2012-07-06</div>
<div class="sdl1 sdz">&lt;/initial_release_date&gt;</div>
</div><div class="sdl1 sds">&lt;last_release_date&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-m170B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m170&#39;)" style="display:none" /><img id="sdiff-collapse-m170B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m170&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/date&gt;</div>
<div id="sdiff-collapse-m170B-cdiv" class="sdiff-collapsed" title="The middle 347 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m170&#39;)" style="display:none"></div><div id="sdiff-collapse-m170B-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/status_block&gt;</div>
<div class="sdl1 sds">&lt;start_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2012-11</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/start_date&gt;</div>
<div class="sdl1 sda">&lt;primary_compl_date</div>
<div class="sdl1"> type=&quot;Anticipated&quot;</div>
<div class="sdl1">&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2018-11</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/primary_compl_date&gt;</div>
<div class="sdl1 sds">&lt;phase_block&gt;</div>
<div class="sdl2 sds">&lt;phase&gt;</div>
<div class="sdl3">  Phase 1</div>
<div class="sdl2 sdz">&lt;/phase&gt;</div>
<div class="sdl2 sds">&lt;phase&gt;</div>
<div class="sdl3">  Phase 2</div>
<div class="sdl2 sdz">&lt;/phase&gt;</div>
<div class="sdl1 sdz">&lt;/phase_block&gt;</div>
<div class="sdl1 sds">&lt;study_type&gt;</div>
<div class="sdl2">  Interventional</div>
<div class="sdl1 sdz">&lt;/study_type&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Treatment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Randomized</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Open Label</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Single Group Assignment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Safety/Efficacy Study</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;number_of_arms&gt;</div>
<div class="sdl2">  2</div>
<div class="sdl1 sdz">&lt;/number_of_arms&gt;</div>
<div class="sdl1 sds">&lt;primary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Maximum Tolerated Dose (MTD)</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  28 days</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Maximum tolerated daily oral dose defined as &amp;lt;33% of patients experiencing a dose limiting toxicity (DLT) during Cycle 1.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  Yes</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/primary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Anti-Tumor Effects</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  28 days</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Response rate estimated by Bayesian posterior estimates, along with the 95% credible intervals for the two treatment arms. Survival or times to failure and time to progression functions estimated using the Kaplan-Meier method. Toxicity reported by type, frequency and severity. Highest toxicity grades per patient per course tabulated for selected adverse events and laboratory measurements.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  Yes</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sda">&lt;enrollment</div>
<div class="sdl1"> type=&quot;Anticipated&quot;</div>
<div class="sdl1">&gt;</div>
<div class="sdl2">  96</div>
<div class="sdl1 sdz">&lt;/enrollment&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Leukemia</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;arm_group&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Cytarabine + Tosedostat</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_type&gt;</div>
<div class="sdl3">  Experimental</div>
<div class="sdl2 sdz">&lt;/arm_type&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Phase I Arm A: Starting dose of Cytarabine 7.5 mg subcutaneous (SQ) twice daily (BID) for 10 days every 28 days. Dose escalation will proceed up to the Target dose level (dose level 0) 10 mg SQ BID for 10 days.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Phase II (Randomized) Starting dose of Cytarabine: Maximum tolerated dose from Phase I.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Phase I and II Tosedostat: 120 mg by mouth daily. After the first 4 weeks of therapy, a dose escalation to 180 mg daily may be considered for patients not achieving a CR provided the patient has not experienced any grade &amp;gt;/= 3 toxicity. Such instances should be discussed with the principal investigator and the sponsor and assessed on a case-by-case basis.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl1 sdz">&lt;/arm_group&gt;</div>
<div class="sdl1 sds">&lt;arm_group&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  5-Azacytidine + Tosedostat</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_type&gt;</div>
<div class="sdl3">  Experimental</div>
<div class="sdl2 sdz">&lt;/arm_type&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Phase I Arm B: Starting dose of 5-azacytidine 50 mg/m2 by vein (IV) or subcutaneously (SQ) daily for 7 days, on days 1-7 every 28 days. Dose escalation will proceed up to the Target dose level (dose level 0) 75 mg/m2 IV (or SQ) daily for 7 days, on days 1-7.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Phase II (Randomized) Starting dose of 5-azacytidine:  Maximum tolerated dose from Phase I.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Phase I and II Tosedostat: 120 mg by mouth daily. After the first 4 weeks of therapy, a dose escalation to 180 mg daily may be considered for patients not achieving a CR provided the patient has not experienced any grade &amp;gt;/= 3 toxicity. Such instances should be discussed with the principal investigator and the sponsor and assessed on a case-by-case basis.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl1 sdz">&lt;/arm_group&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  Cytarabine</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Phase I Arm A: Starting dose of Cytarabine 7.5 mg subcutaneous (SQ) twice daily (BID) for 10 days every 28 days. Dose escalation will proceed up to the Target dose level (dose level 0) 10 mg SQ BID for 10 days.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Phase II (Randomized) Starting dose of Cytarabine: Maximum tolerated dose from Phase I.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Cytarabine + Tosedostat</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  Ara-C</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  Cytosar</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  DepoCyt</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  Cytosine Arabinosine Hydrochloride</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  5-Azacytidine</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Phase I Arm B: Starting dose of 5-azacytidine 50 mg/m2 by vein (IV) or subcutaneously (SQ) daily for 7 days, on days 1-7 every 28 days. Dose escalation will proceed up to the Target dose level (dose level 0) 75 mg/m2 IV (or SQ) daily for 7 days, on days 1-7.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Phase II (Randomized) Starting dose of 5-azacytidine: Maximum tolerated dose from Phase I.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  5-Azacytidine + Tosedostat</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  Azacitidine</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  5-aza</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  Vidaza</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  5-AZC</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  AZA-CR</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  Ladakamycin</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  NSC-102816</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  Tosedostat</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Phase I: 120 mg by mouth daily.  After the first 4 weeks of therapy, a dose escalation to 180 mg daily may be considered for patients not achieving a CR provided the patient has not experienced any grade &amp;gt;/= 3 toxicity.  Such instances should be discussed with the principal investigator and the sponsor and assessed on a case-by-case basis.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Phase II: 120 mg by mouth daily. 120 mg by mouth daily during induction (i.e., first 28 days of therapy).  After the first 4 weeks of therapy, a dose escalation to 180 mg daily may be considered for patients not achieving a CR provided the patient has not experienced any grade &amp;gt;/= 3 toxicity.  Such instances should be discussed with the principal investigator and the sponsor and assessed on a case-by-case basis.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Cytarabine + Tosedostat</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  5-Azacytidine + Tosedostat</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;eligibility&gt;</div>
<div class="sdl2 sds">&lt;criteria&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Inclusion Criteria:</div>
<div class="sdl4">  </div>
<div class="sdl4">  1)	Signed, informed consent must be obtained prior to any study specific procedures.</div>
<div class="sdl4">  </div>
<div class="sdl4">  2)	For the phase I portion of the study patients should have failed any number of prior therapies, which should include at least the following: 1. Patients with MDS should have failed prior therapy with a hypomethylating agent and/or with lenalidomide. 2. Patients with AML should have failed any prior induction therapy or have relapsed after prior therapy. 3. Patients with MDS who received therapy with a hypomethylating agent and progress to AML are eligible at the time of diagnosis of AML regardless of any prior therapy for AML. 4. Patients with any of the eligible diagnoses who have received no prior therapy are eligible if not candidates to receive standard therapy or if they refuse standard chemotherapy.</div>
<div class="sdl4">  </div>
<div class="sdl4">  3)	For the phase II Portion of the study, only patients who are previously untreated for AML. 1. Patients with history of MDS who received therapy for MDS and progressed to AML are eligible at the time of diagnosis of AML. Only induction chemotherapy administered for AML will be considered for considerations of eligibility regarding prior therapy. Patients who received therapy for MDS before transforming to AML (e.g., with hypomethylating agents or lenalidomide) are eligible.</div>
<div class="sdl4">  </div>
<div class="sdl4">  4)	ECOG performance status of 0-2.</div>
<div class="sdl4">  </div>
<div class="sdl4">  5)	Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must use acceptable contraceptive methods (abstinence, intrauterine device [IUD], oral contraceptive or double barrier device) while on study and must continue to do so for 3 months after stopping study drug, and must have a negative urine or serum pregnancy test within 2 weeks prior to beginning treatment on this trial. Sexually active men must also use acceptable contraceptive methods for the duration of time on study. Pregnant and nursing patients are excluded because the effects of tosedostat on a fetus or nursing child are unknown.</div>
<div class="sdl4">  </div>
<div class="sdl4">  6)	Patients must have been off chemotherapy for 2 weeks prior to entering this study, unless there is evidence of rapidly progressive disease, and must have recovered from the toxic effects of that therapy to at least grade 1. Use of hydroxyurea for patients with rapidly proliferative disease is allowed before the start of study therapy and for the first four weeks on therapy.</div>
<div class="sdl4">  </div>
<div class="sdl4">  7)	Patients must have the following clinical laboratory values unless considered due to leukemic organ involvement: 1. Serum creatinine &amp;lt;/= 2.0 mg/dl. 2. Total bilirubin &amp;lt;/= 1.5x the upper limit of normal unless considered due to Gilbert&amp;apos;s syndrome. 3. Alanine aminotransferase (ALT), or aspartate aminotransferase (AST) &amp;lt;/= 3x the upper limit of normal.</div>
<div class="sdl4">  </div>
<div class="sdl4">  8)	Age &amp;gt;/= 60 years</div>
<div class="sdl4">  </div>
<div class="sdl4">  9)	Left ventricular ejection fraction (LVEF) &amp;gt;/= 50% within 28 days prior to first dose of study drug administration</div>
<div class="sdl4">  </div>
<div class="sdl4">  10)	Patient is able to comply with all study procedures including study drug administration, visits and tests</div>
<div class="sdl4">  </div>
<div class="sdl4">  Exclusion Criteria:</div>
<div class="sdl4">  </div>
<div class="sdl4">  1)	Uncontrolled intercurrent illness including, but not limited to uncontrolled infection, symptomatic congestive heart failure (New York Heart Association Class III or IV), or psychiatric illness/social situations that would limit compliance with study requirements.</div>
<div class="sdl4">  </div>
<div class="sdl4">  2)	Active heart disease including myocardial infarction within previous 3 months, symptomatic coronary artery disease, clinically significant arrhythmias not controlled by medication, or uncontrolled congestive heart failure (New York Heart Association Class III or IV).</div>
<div class="sdl4">  </div>
<div class="sdl4">  3)	Patients with APL (FAB type M3) or CML in blast crisis.</div>
<div class="sdl4">  </div>
<div class="sdl4">  4)	Significant gastrointestinal disorders that may interfere with absorption of tosedostat.</div>
<div class="sdl4">  </div>
<div class="sdl4">  5)	Patients who can receive an allogeneic stem cell transplant within 4 weeks.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/criteria&gt;</div>
<div class="sdl2 sds">&lt;healthy_volunteers&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/healthy_volunteers&gt;</div>
<div class="sdl2 sds">&lt;gender&gt;</div>
<div class="sdl3">  Both</div>
<div class="sdl2 sdz">&lt;/gender&gt;</div>
<div class="sdl2 sds">&lt;minimum_age&gt;</div>
<div class="sdl3">  60 Years</div>
<div class="sdl2 sdz">&lt;/minimum_age&gt;</div>
<div class="sdl2 sds">&lt;maximum_age&gt;</div>
<div class="sdl2 sdz">&lt;/maximum_age&gt;</div>
<div class="sdl1 sdz">&lt;/eligibility&gt;</div>
<div class="sdl1 sds">&lt;investigator&gt;</div>
<div class="sdl2 sds">&lt;role&gt;</div>
<div class="sdl3">  Principal Investigator</div>
<div class="sdl2 sdz">&lt;/role&gt;</div>
<div class="sdl2 sds">&lt;name&gt;</div>
<div class="sdl3">  Jorge Cortes, MD</div>
<div class="sdl2 sdz">&lt;/name&gt;</div>
<div class="sdl2 sds">&lt;affiliation&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  UT MD Anderson Cancer Center</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/affiliation&gt;</div>
<div class="sdl1 sdz">&lt;/investigator&gt;</div>
<div class="sdl1 sds">&lt;see_also&gt;</div>
<div class="sdl2 sds">&lt;annotation&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  UT MD Anderson Cancer Center Website</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/annotation&gt;</div>
<div class="sdl2 sds">&lt;url&gt;</div>
<div class="sdl3">  http://www.mdanderson.org</div>
<div class="sdl2 sdz">&lt;/url&gt;</div>
<div class="sdl1 sdz">&lt;/see_also&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Leukemia</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Acute Myeloid Leukemia</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  AML</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Myelodysplastic Syndromes</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  MDS</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Relapsed</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Refractory</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Cytarabine</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  ARA-C</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Cytosar</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  DepoCyt</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Cytosine Arabinosine</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  5-Azacytidine</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Azacitidine</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  5-aza</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Vidaza</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  5-AZC</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  AZA-CR</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Ladakamycin</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  NSC-102816</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Tosedostat</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;initial_release_date&gt;</div>
<div class="sdl2">  2012-07-06</div>
<div class="sdl1 sdz">&lt;/initial_release_date&gt;</div>
</div><div class="sdl1 sds">&lt;last_release_date&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-m4"><td class="sdiff-h">4</td>
<td class="sdiff-a"><div class="sdl2"><span class="sdwc">2013-03-08</span> </div>
</td>
<td class="sdiff-b"><div class="sdl2"><span class="sdwc">2013-04-24</span> </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-m5"><td class="sdiff-h">5</td>
<td class="sdiff-a"><img id="sdiff-collapse-m520A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m520&#39;)" style="display:none" /><img id="sdiff-collapse-m520A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m520&#39;)" style="display:none" /><div class="sdl1 sdz">&lt;/last_release_date&gt;</div>
<div id="sdiff-collapse-m520A-cdiv" class="sdiff-collapsed" title="The middle 4 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m520&#39;)" style="display:none"></div><div id="sdiff-collapse-m520A-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;init_disposition_release_date&gt;</div>
<div class="sdl1 sdz">&lt;/init_disposition_release_date&gt;</div>
<div class="sdl1 sds">&lt;init_results_release_date&gt;</div>
<div class="sdl1 sdz">&lt;/init_results_release_date&gt;</div>
</div><div class="sdl0 sdz">&lt;/clinical_study&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-m520B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m520&#39;)" style="display:none" /><img id="sdiff-collapse-m520B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m520&#39;)" style="display:none" /><div class="sdl1 sdz">&lt;/last_release_date&gt;</div>
<div id="sdiff-collapse-m520B-cdiv" class="sdiff-collapsed" title="The middle 4 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m520&#39;)" style="display:none"></div><div id="sdiff-collapse-m520B-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;init_disposition_release_date&gt;</div>
<div class="sdl1 sdz">&lt;/init_disposition_release_date&gt;</div>
<div class="sdl1 sds">&lt;init_results_release_date&gt;</div>
<div class="sdl1 sdz">&lt;/init_results_release_date&gt;</div>
</div><div class="sdl0 sdz">&lt;/clinical_study&gt;</div>
</td>
</tr>

</table></div></form><div class="navBottom"><div class="navBottomLine" style="background-image: url(/archive/ctgov_logo_ttm.gif)">&#160;</div><div class="navBottomLinks">&#160;</div></div><script>
SDiffDeclareUnchCRID('sdiff-collapse-f0');
SDiffDeclareUnchCRID('sdiff-collapse-f170');
SDiffDeclareUnchCRID('sdiff-collapse-f556');
SDiffDeclareUnchCRID('sdiff-collapse-m0');
SDiffDeclareUnchCRID('sdiff-collapse-m170');
SDiffDeclareUnchCRID('sdiff-collapse-m520');
SDiffInit();
</script></body></html>